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Background and Objectives: Sugar substitutes have gained popularity in the management of 
diabetes, obesity and related diseases, due to their low calorie content compared to sucrose. 
Recent studies have reported that xylitol, a commonly used sugar alcohol has anti-diabetic 
properties. This study was therefore conducted to investigate the possible mechanism(s) behind 
the anti-diabetic effects of xylitol. 
Materials and Methods: This study was carried out by investigating both in vitro, ex vivo and in 
vivo mechanisms. For in vitro studies, the inhibitory effects of different concentrations of xylitol 
(2.5, 5, 10, 20, 30 and 40%) on carbohydrate hydrolyzing and digestive enzymes; alpha-amylse 
and alpha-glucosidase were investigated. For the ex vivo studies, seven-week-old normal adult 
male Sprague-Dawley rats (B.W. 180-200 g) were sacrificed and the jejunum and psoas muscles 
were collected. The effect of increasing concentrations of xylitol (10, 20 and 40%) on intestinal 
glucose absorption was then examined in isolated rat jejunum. A 3 mM acarbose was used as 
positive control. Additionally, the effect of increasing concentrations of xylitol on muscle 
glucose uptake, with and without insulin (100 mU/mL) was investigated in the isolated rat psoas 
muscles, when 1mg/mL metformin was used as positive control. For the in vivo studies, adult 
Spagrue Dawley rats were randomly divided into five groups: normal control (NC), normal 
xylitol (NXYL), diabetic control (DBC), diabetic xylitol (DXYL) and diabetic acarbose (DBA). 
Type 2 diabetes was induced in the DBC, DXYL and DBA groups. After confirmation of 
diabetes, animals were fasted overnight for 16 hours, and a single bolus dose of either glucose 
(for NC and DBC groups) or glucose and xylitol (for NXYL and DXYL groups) or glucose and 
acarbose (for DBA group) solutions was orally administered to rats along side with 0.05% w/v 
phenol red as recovery marker. Animals were sacrificed exactly 1 hr after dose administration, 
and glucose absorption and related parameters were estimated in different segments of the 
gastrointestinal tract (GIT). 
Results: Increasing concentrations of xylitol showed increasing inhibition of 4 U/mL alpha-
amylase (IC50 = 21.69 xylitol) and 1 U/mL alpha-glucosidase (IC50 = 17.58 xylitol) activities 
with the highest inhibition at 30% and 40%. Also increasing concentrations of xylitol showed 
lower glucose intestinal absorption, which was significantly lower at 40% Xylitol compared to 
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the control, 10 and 20% xylitol, but only relatively lower compared to 3mM acarbose. 
Furthermore, increasing concentrations of xylitol showed increasing glucose muscle uptake, 
which was significantly higher at 40% Xylitol compared to the control, but only relatively higher 
compared to 10, 20% xylitol and 1 mg/mL metformin. The presence of insulin did not 
significantly affect muscle glucose uptake of xylitol. Additionally, oral single bolus dose of 
xylitol inhibited small intestinal glucose absorption, delayed gastric emptying and accelerated 
digesta transit in the GIT compared to the respective controls. Acarbose did not significantly 
affect intestinal glucose absorption in both in vivo and in vitro conditions. 
Discussion and conclusion: The anti-diabetic effects of xylitol may not only be due to the 
slower gastric emptying and lower carbohydrate digestion and glucose absorption from the small 
intestinal mucosa. It may also be due to improving insulin action or exhibiting an insulin-like 
effect on skeletal muscle, thus increasing muscle glucose uptake and utilization, which may also 

































Diabetes is a major threat to global public health that is imposing socio-economic burden around 
the world especially in the developing countries. The prevalence of this disease is increasing at 
an alarming ratedue to population growth, aging, urbanization, and increasing prevalence of 
obesity and physical inactivity (Wild etal., 2004). About 171 million peoplewere with diabetes in 
the year 2000 whichhas been projected to become about 336 million people in the year 2030 
(Wild et al., 2004). Supporting this projection, this figure was already more than 371 million 
people in 2012 and more than 471 billion USD was spent on health care expenditure for diabetes 
in the same year (IDF, 2012). 
 
TABLE 1.1: Global estimate and prevalence of people with diabetes (20-79 years) in 2012 and 
2030 (IDF Diabetes atlas, 5th edition, 2012 updates). 
 2012 2030 




Comparative diabetes prevalence (%)  8.3 8.9 
   
 
 
Furthermore,the mortality rate of diabetes is also increasing concomitantly with its prevalence. 
According to the International Diabetes Federation (2012),about 4.8 million people died in 2012 
due to diabetes, which was approximately 8.6% of all-cause of mortality and about 4.2% higher 
than 2011. There is therefore a great need for more research to discover better and more strategic 





FIGURE 1.1: Global healthcare expenditures and deaths per 1,000 due to diabetes by income 
group in 2012 (IDF Diabetes atlas, 5th edition, 2012 updates). 
 
Like other parts of the world, diabetes has also become a serious issue in Africa. In South Africa 
for example, IDF estimated that approximately 1.9 million of 30 million adults between 20 to 79 
years are with diabetes (Amodetal., 2012). It is quite unfortunate that diabetes and its 
complications are increasing at an alarming rate, especially among the people in black and Indian 
community, and about 50-85% of diabetes sufferers (especially in rural areas) remain 









FIGURE 1.2: Global map showing regional estimates and prevalence of people with diabetes 
(20-79 years) in 2012 (IDF Diabetes atlas, 5th edition, 2012 updates). 
 
Among the types of diabetes, type 2 diabetes (T2D) is known to have the highest prevalence, 
which is between 90% - 95% of all diabetes cases (Loghmani, 2005; Sheri et al., 2010). This 
research is therefore focused on T2D, because of its higher prevalence compared to other types 
and the dietary related factors associated with it, having in mind today’s poor and unhealthy 
eating style. 
NORTH AMERICA AND 
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Artificial or synthetic sweeteners such as saccharin, acesulfame potassium (Ace-K), sucralose, 
neotame and aspartame have been known to be sugar substitutes especially for diabetic 
individuals because of their significantly higher sweetness than sucrose with very low or no 
calorific values (Islam and Indarjit, 2012). Nevertheless, the short or long term chronic 
consumption of these sweeteners is associated with a number of adverse effects on 
health(Abdelaziz and Ashour, 2011; Bell et al., 2002; Clayson, 1984; Kroger et al., 2006), which 
has been a major concern to consumers. For these reasons natural sweeteners like honey, high 
fructose corn syrup, fructose, maple syrup, molasses etc. are usually used as alternative source of 
sweeteners. However, it has been reported that the chronic or over consumption of these 
sweeteners may cause severe health problems such as overweight, obesity, type 2 diabetes (T2D) 
and many other diseases related to metabolic syndrome (Stanhope, 2011). On the other hand, 
sugar alcohols are preferred alternatives to other natural and artificial sweeteners, and more 
attention has been given to xylitol because of its better effects on health compared to other sugar 
alcohols and, lower caloric value (2.4 kcal vs 4.0 kcal/g), insulinemic response, lower glycemic 
index (13) and  similar sweetness compared to sucrose (Islam, 2011). 
Additionally, xylitol has several unique beneficial effects such as dental protection (Spliethet al., 
2009; Twetman, 2001) and control and prevention of obesity, diabetes and related metabolic 
disorders (Amoet al., 2011; Islam, 2011; Islam and Indarjit, 2012; Kishore et al., 2012). Xylitol 











1.2 Aim and Objectives 
In a recent study, it was reported that xylitol can be a better sweetener than sucrose to maintain 
diabetes-related parameters at physiologically safer and stable conditions (Islam, 2011).In 
another study, the in vivo anti-diabetic effects of xylitol were reported (Islam and Indarjit, 2012). 
In these studies, xylitol significantly reduced the NFBG and also improved most diabetes-related 
parameters in normal and T2D model of rats. Furthermore, it has been reported that xylitol 
consumption significantly prolongs gastric emptying, decreases food intake and accelerates 
intestinal transit of nutrients compared to glucose, fructose and some other polyols in normal 
human subjects and experimental animals (Salminenetal., 1984 and 1989; Shafer etal., 1987). 
This was demonstrated in a recent study (Islam and Indarjit, 2012), where lower food and fluid 
intake was reported in rats fed with 10% xylitol solution compared to the diabetic control. In this 
study, it was predicted that faster intestinal transit and slower gastric emptyingmight reduce the 
rate of intestinal nutrient absorption. It could be possible that xylitol may have delayed intestinal 
absorption of glucose or prevented the digestion of carbohydrate by digestive enzymes such as 
alpha glucosidase and alpha amylase, thus lowering NFBG and reducing food intake compared 
to diabetic control rats. Furthermore, as mentioned above, insulin plays a significant role in the 
cell uptake of circulating glucose. We speculate that the insulinotropic effect of xylitol, as 
reported by Islam and Indarjit (2012) might be involved in improving circulating glucose uptake, 
especially in muscle and fat cells. However, these possiblemechanism(s) behind the anti-diabetic 
effects of xylitol have not been studied, especially under diabetic condition. The present study 
was therefore aimed at investigating the possible mechanism(s)behind the anti-diabetic effects of 
































T2D is identified by hyperglycemia, insulin resistance and relative insulin deficiency (Olokobaet 
al., 2012). The classic symptoms of T2D are excess thirst, frequent urination and constant 
hunger. In progressive cases T2D can cause complication like cardiovascular diseases (CVD), 
kidney diseases, nerve diseases and blindness, which is a significant cause of mortality and 
morbidity (Colberget al., 2010). 
During T2D,there exist inadequate response of myocytes and adipocytes to insulin and 
subsequent insufficient insulin production to compensate for this defect (Colberget al., 2010). 
Inadequate insulin production from beta cells, also known as impaired glucose induced insulin 
secretion is caused by progressive beta-cell dysfunctions, which contributes to persistent 
hyperglycemia.Some genetic and environmental factors are also involved in the development of 
T2D. The role of genetic implications has not been clearly defined (ADA, 2010). Environmental 
factors include dietary factors and life style. For example, high consumption of simple 
carbohydrates and saturated fats combined with inadequate exercise can result in obesity 
followed by insulin resistance and T2D. The risk of T2D is believed to increase with obesity, 
hypertension or dyslipidemia, physical inactivity and age (Colberget al., 2010; Warjeet, 2011). 
 
2.2 Carbohydrate Metabolism and Blood Glucose Regulation 
Carbohydrate (CHO) from starch is a major human dietary source of glucose, a product of 
hydrolysis. This is absorbed in the small intestine, influencing postprandial blood glucose levels. 
Thusthe rate and extent of CHO digestion and glucose absorption is linked to glycemia-related 
problems like diabetes, obesity and related metabolic disorders (Dhitalet al., 2013). CHO is 
broken down or hydrolyzed into smaller oligosaccharides, disaccharides and monosaccharides by 
important CHO hydrolyzing enzymes, alpha amylase (AM) and alpha glucosidase (AG). 
Alpha amylases are a group of calcium dependent enzymes that catalyzes the random break 
down of amylose and amylopectin units in starch to yield smaller CHO units like maltotriose, 
maltose and glucose (Qianet al., 1997). They are known to hydrolyze the alpha bonds of alpha-
linked polysaccharides. In human, they are found in several tissues, but are mostly present in the 
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saliva and pancreatic juice, which both have similar amino acid sequences (Paseroet al., 1986). 
Salivary AM is most effective at an optimum pH between 6.7 to7.0. It is usually inactivated in 
the stomach by the acidic pH of gastric acid, but studies have shown that both starch and 
products from starch hydrolysis are able to protect salivary AM from gastric acid inactivation 
(Rosenblumet al.,1988). 
Alpha glucosidases are a group of enzymes that belong to the family of the glycoside hydrolases, 
which catalyzes the release of alpha glucose from the reducing terminal end of alpha glycosyl 
residue-possessing substrates (Okuyamaet al., 2005). In human, they are present in the intestinal 
mucosa as two membrane bounded protein complexes (maltase-glucoamylase and sucrase-
isomaltase), which catalyzes from the reducing, end the hydrolysis of α-1,4-glycosidic linkages 
resulting from AM starch degradation to form free glucose (Dhitalet al., 2013). 
Glucose resulting from the digestion of starch and other carbohydrates is absorbed into the blood 
via the wall of the duodenum. The rate of gastric emptying and intestinal transit of nutrient is an 
important factor in gastrointestinal nutrient digestion and absorption (Islam and Indarjit, 2012). 
Nutrient gastric emptying is the movement of ingested food down into the small intestine from 
the stomach, while nutrient intestinal transit time is the time it takes ingested food to travel 
through the entire length of the intestine. It is believed that faster intestinal transit and delayed 
gastric emptying of nutrient may be the cause of slow intestinal nutrient absorption and reduced 
food intake (Salminenet al., 1984; Shafer et al., 1987). 
Furthermore, the rate and manner of gastric emptying and intestinal transit of ingested food 
partly depends on the nature and concentration of what was ingested (Elias et al., 1968; Moran 
and McHugh, 1981). For example, fructose is emptied from the stomach more quickly than 
glucose, while some polyols like xylitol, sorbitol and lactitol have shorter intestinal transit time 
than glucose, which is believed to be a major contributor to abdominal pain and diarrhea 
normally experienced by normal individuals after ingesting moderate to large amounts of 
fructose and the above-mentioned polyols (Salminenet al., 1989). 
Unlike fructose and polyols, these abdominal discomforts do not occur after ingestion of 
equivalent or comparable amounts of glucose. Studies have shown that aqueous glucose solution 
has an exponential gastric emptying rate that is inversely proportional to its concentration (Elias 
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et al., 1968). In fact, unlike fructose, ingestion of glucose stimulates gastric inhibitory peptide 
(GIP) secretion (Sykes et al., 1980), which has been reported to play a major role in the proposed 
mediation of delayed gastric emptying by enterogastrone  hormone (Brown, 1982). Despite the 
slow gastric emptying rate of glucose solution, glucoseis not rapidly transported along the 
intestine. In a study conducted by Salminenet al.,(1989) on normal subjects to examine the 
gastrointestinal transit rate of glucose compared to xylitol, glucose travelled through the intestine 
at a much slower rate, which was attributed to its rate and manner of absorption. 
Once glucose is absorbed, it immediately moves into the blood and circulation. The body 
therefore possesses appropriate mechanisms to ensure physiological blood glucose homeostasis 
(Figure 2.1). Glucose is removed from the blood when not in use by converting excess blood 
glucose to glycogen which is stored in the liver. When the body requires energy for normal 
physiological functions, and when there is a fall in blood glucose level, stored glycogen is 
broken down into glucose, which is then released into the blood (Mathews et al., 2000). 
Glucagon and insulin are the two major hormones in the body that work consistently to regulate 
and maintain physiological blood glucose homeostasis. 
 
 
FIGURE 2.1:Hormonal regulation of blood glucose level (Mathews et al., 2000). 
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Glucagon is produced by the alpha cells of the pancreas when there is low blood glucose. 
Glucagon hormone causes the cAMP dependent activation of glycogen phosphorylase, which 
then catalyzes the phosphorylytic breakdown of glycogen to release glucose-6-phosphate into the 
blood(Jiang and Zhang, 2003). Glucagon hormone also promotes gluconeogenesis when 
glycogen reserve is very minimal. When blood glucose rises, either due to glycogen break down 
or intestinal glucose absorption, the beta-cells of the pancreas releases insulin which promotes 
cell glucose uptake via cell membrane glucose transporter type 4 (GLUT 4); glycolysis; 
inhibition of glucagon secretion by alpha cells; and also signals the activation of glycogen 
synthase that catalyzes the conversion of glucose to glycogen, thus normalizing blood glucose 
level (Mathews et al., 2000). Insulin resistance is a major disorder in glucose metabolism and 
homeostasis that can contribute to hyperglycemic conditions in T2D. 
 
2.3 Insulin Resistance 
Insulin resistance is involved in the progression of T2D. For example, during the onset of T2D, 
there may exist normal blood glucose condition, while the individual gradually develops insulin 
resistance and subsequent inadequate blood glucose uptake. If this remains undiagnosed and 
untreated, it may contribute to persistent hyperglycemia in T2D. Insulin resistance has been 
found to be associated with a number of factors, which include genetic factors and environmental 
factors. However, environmental factors such as inactivity or lack of exercise, aging, type of diet 
and obesity are still the most influencing factors that can contribute to the development of insulin 
resistance (Kahn, 2003). 
Insulin resistance occurs when affected cells such as myocytes,adipocytes and hepatocytes do 
not effectively respond to insulin hormone signaling. Cells become insensitive to insulin and thus 
the release of insulin hormone into the blood does not effectively normalize blood glucose level. 
However, the effect of insulin resistance can vary from one organ or tissue to another. For 
example, in the liver, it can result in reduced glycogenesis and glycogen storage and increased 
glycogenolysis and release of glucose into circulation, while muscle and fat cells donot 





FIGURE 2.2: Cells showing insulin resistance and insulin sensitivity (www.encyclopedia.com). 
 
Apart from blood glucose regulation and homeostasis, insulin is also important in the regulation 
of body fat metabolism. It is critical for promoting uptake of circulating free fatty acid (FFA); 
differentiation and maturation of adipocytes; lipogenesis; and inhibition of lipolysis (Kahn and 
Flier, 2000). Therefore, a defect in fat metabolism, subsequent abnormally high plasma FFA and 
triacylglyceride and abnormally low plasma high density lipoprotein levels can occur during 
insulin resistance, which can predispose an insulin resistant patient to obesity, metabolic 
syndrome and other diabetes related complications (Haag and Dippenaar, 2005; Rabolet al., 
2011). 
In order to compensate for insulin resistance and insensitivity of cells, more insulin is being 
released into the blood. This will eventually cause hyperinsulinemia, a condition where there is 
an abnormally high plasma insulin level. Hyperinsulinemia will signal for more energy storage 
into adipocytes, new fatty tissues formation and hunger, thus promoting weight gain, a major 




2.4 Pancreatic Beta cell Dysfunction and Impaired Insulin Secretion in T2D 
The pancreas is the sole organ that produces insulin in the body. It is predominantly dominated 
with beta cells among several types of secretory cells,which collectively make up the islet of 
langerhans within the pancreas. Insulin hormone is secreted by these endocrine secretory beta-
cells, and progressive beta-cell failure is associated with the development of type 1 and T2D.  
Beta-cell failure is caused by auto-immune related beta-cell damage in type 1 diabetes, while 
insulin resistance related factors play a major role in the development of beta-cell failure in T2D, 
which is manifested by failure of glucose to stimulate insulin secretion by beta-cells (Cnopet al., 
2005; Ogawa et al., 1992). 
As previously stated, insulin resistance can cause hyperinsulinemia, when the body tries to 
compensate for insulin insensitivity of cells by producing more insulin. This abnormally high 
demand for production and secretion may eventually exhaust the beta-cells, thus leading to 
impaired insulin secretion and glucose intolerance, which in the presence of persistent 
hyperglycemia forms the major characteristics ofT2D (Cnopet al., 2005; Li et al., 2011). 
 
FIGURE 2.3: Schematic diagram showing the changes in beta-cell mass accompanying 
progression of T2D (Souza et al., 2006). 
 
In a previous study, Ogawa et al.,(1992) were able to provide some evidences supporting the 
correlation between insulin resistance, beta-cell dysfunction and impaired insulin secretion as 
major characteristics of T2D.They observed that the islet mass and other indices of insulin 
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resistance in insulin resistant diabetic rats were lesser compared to insulin resistant non-diabetic 
rats, indicating inadequate compensation by beta-cells for insulin resistance and impaired insulin 
secretion in the diabetic rats. From these observations, they reported that insulin resistance alone 
was not sufficient to cause T2D in the diabetic rats, suggesting the presence of a concomitant 
beta-cell disorder whenever diabetic hyperglycemia due to insulin resistance occurred. 
Supporting this, Cnopet al., 2005 hypothetically reported that a disorder in glucose-induced 
insulin secretion (GIIS) during the development of T2D in human may be as a result of a 
derangement in beta-cell function and mass.  
Furthermore, under hyperglycemic conditions, glucotoxicity may occur, which may adversely 
affect the mass, function and survival of beta-cells. This is believed to be a majorcontributor to 
GIIS in T2D (Cnopet al., 2005). Although, the mechanism behind hyperglycemic glucotoxicity 
on beta-cells still remains a debate, several studies have reported reduced expression of 
pancreatic GLUT 2 and glucokinase genes and subsequent reduced GIIS in diabetic insulin 
resistant rats (Cnopet al., 2005; Ogawa et al., 1992). 
Several therapeutic approaches have been used to ameliorate diabetes. These approaches range 
from synthetic drugs and medicinal plants to dieting and exercise. For T2D, treatment is 
achieved by controlling the intake of calorie-rich and postprandial blood glucose-increasing diet 
and use of hypoglycemic drugs (Patelet al., 2012). However some therapeutic agents are also 
aimed at preventing and treating diabetes related complications and metabolic syndrome. 
 
2.5 Therapeutic Agents for Treatment of T2D and Their Modes of Action 
There are several anti-hyperglycemicand glucose lowering agents that are used in the treatment 
of T2D. They act differentlyto maintain lowblood glucose. Most of them are orally administered, 
except for insulin and insulin preparations which are administered parenterally (Warjeet, 2011). 
Most of these anti-diabetic drugs have been tried on experimental models like rodents, in which 
T2D has been induced by pharmacological, surgical or genetic manipulations to examine anti-
diabetic effects (Frӧde and Medeiros, 2008). Depending on their mechanism of action, anti-
diabetic drugs or agents used in the treatment of T2D are classified into several groups such as: 
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insulin and insulin secretagogues, insulin sensitizers, suppressor of hepatic glucose production, 
alpha glucosidase inhibitors and so on. 
 
2.5.1 Insulin and Insulin Secretagogues 
Most type 2 diabetic patients may eventually develop progressive pancreatic beta-cell failure and 
impaired insulin secretion, and as such may need insulin to control hyperglycemia (Hamaty, 
2011). Insulin as a drug is an injectableanalogue of the normal physiological insulin with similar 
function of promoting cell uptake of glucose, glucose disposal and storage of glucose as 
glycogen, thus lowering blood glucose level. Therapeutic insulin is divided into two types 
depending on the mode of action: long-acting (basal) insulin, which is usually taken at bed time 
to maintain normal blood glucose and rapid acting (prandial or bolus) insulin which is usually 
injected after a meal to control postprandial blood glucose rise (Hamaty, 2011). 
Insulin secretagogues(ISs) are T2D medications that are used to remedy impaired insulin 
secretion in type 2 diabetic patients. They help the pancreas to produce and secret insulin for 
blood glucose homeostasis (Patel et al., 2012). Some existing commonly used insulin 
secretagogues are the sulphonylureas like glyburide, gliclazide and glipizide, which are 
sometimes used in combination with other hypoglycemic agents. However, it has been reported 
that this class of ISs are associated with hyperinsulinemia; risk of hypoglycemia; inadequate 
glycemic control (in type 2 diabetes patients); gradual failure in beta-cell function; and weight 
gain, while meglitinides like repaglinde, which is another class of ISs and a prandial glucose 
regulator is believed to have better glycemic control and lower risk of hypoglycemia than 
sulphonylureas (Davies, 2002). 
 
2.5.2 Insulin Sensitizers 
Insulin resistance and insensitivity in the body tissue, especially in the muscles are major 
metabolic defects associated withT2D.Insulin produced cannot adequately induce blood glucose 
uptake or disposal in these tissues, which contributesto hyperglycemia. Insulin sensitivity 
improvement drugs, such as thiazolidines (TZDs)and biguanides like metforminwork by 
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improving the insulin insensitivity and insulin dependent glucose uptake in muscles and other 
tissues, hence improving metabolic control in T2D patients (Hauner, 2002; Klip and Leiter, 
1990; Sirtori and Pasik, 1994). Although, the mechanism or mode of action of TZDs as anti-
diabetic agents at molecular level still remains unclear, it has been reported that TDZs can reduce 
serum glucose, insulin and triglyceride level and also increase blood glucose uptake when used 
to treat type 2 diabetic patients (Kahn et al.,2000). Hauner (2002) reported that the mechanism of 
action of TDZs involves a Peroxisome proliferator-activated receptor gamma (PPAR-γ)-
dependent transcription control of genes involved in glucose and fat metabolism in adipose and 
muscle tissues, which are promoted via an endocrine signal from adipocytes. 
Common anti-diabetic drugs belonging to this class include bigaunides (e.g. metformin), 
troglitazone, rosiglitazone and pioglitazone. Some have been hypothesized to have potential 
therapy against T2D related complications such ascardiovascular diseases (Charbonnelet al., 
2004; Hauner, 2002). Despite this, some TDZs like rosiglitazone is believed to be associated 
with some adverse effects like risk of weight gain, coronary heart disease, heart attack and some 
other vascular disease (Hussein et al., 2004). 
Metformin treatment has been reported to be associated with vitamin B12deficiency and 
increased risk of lactic acidosis especially in individuals with renal or CVD  (Bailey and Turner, 
1996; liuet al., 2006). However it has been reported to be associated with reduced risk of 
cardiovascular diseases (CVD)and all-cause mortality in type 2diabetic patients with obesity and 
some beneficial effects compared to some anti-diabetic drugs such as sulphonylureas, insulin etc 
(Ekstrom et al., 2012; Kahn et al., 2006; Kooyet al., 2009). Studies conducted by Ekstrӧmet 
al.,(2012) showed lower risk of CVD and acidosis or serious infection in metformin treated type 
2 diabetic patients than some oral glycemic drugs and insulin, concluding that the beneficial 
effects of metformin outweighs the risk of adverse effects. 
 
2.5.3 Suppressors of Hepatic Glucose Production 
Hepatic glycogenolysis and gluconeogenesis are two glucagon-dependent glucose production 
processes that serves as major sources of glucose for body metabolic functions, during fasting 
and when blood glucose drops. The inability of insulin to suppress these processes and the 
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hormonal and enzymatic factors that promotes them is a major etiological factor in the 
development of hyperglycemia in type 2 diabetic patients (DeFronzoet al., 1982; Posticet al., 
2004). These processes, which are cyclic AMP (cAMP) dependent,are believed to be major 
targets for some classes of anti-diabetic drugs (Milleret al., 2013).Glucagon binding to cell 
membrane receptors causes the activation of adenylatecyclase, and subsequent cAMP 
production, which activates protein kinase A (PKA). Activated PKA phosphorylates and 
activates target proteins that signals or up regulates hepatic glucose output (Jiang and Zhang, 
2005). 
Anti-diabetic drug belonging to this class act by down regulating glycogenolysis and 
gluconeogenesis, which are major processes that increase hepatic glucose output.Thus, reducing 
the amount of glucose going into circulation when there is high blood glucose level. Although 
the molecular mechanism behind the anti-diabetic action of biguanides have been previously 
suggested to be via the enhancement of glucose disposal and activation of the enzyme AMP-
activated protein kinase (AMPK), a cellular glucose uptake inducer (Goodazi and Bryer-Ash, 
2005; Inzucchiet al., 1998; Zhou etal., 2001),recent studies have reported biguanides to be a 
suppressor of hepatic glucose production (Viollet et al., 2012), and metformin an antagonist of 
glucagon action (Miller et al., 2013).According to Miller et al., 2013, metformin treated mouse 
exhibited accumulation of AMP (an adenylatecyclase inhibitor) in the liver cells and increased 
PKA activity and target protein phosphorylation, indicatingsuppression or blocking of glucagon-
dependent hepatic glucose output and hypoglycemic function. 
 
2.5.4 Alpha Glucosidase Inhibitors 
This class of oral glycemic drug work by preventing postprandial hyperglycemia (Reuser and 
Wisselaar, 1994). They delay the digestion of carbohydrate like starch and sucrose, and also 
delay the subsequent absorption of absorbable monosaccharides like glucose resulting from 
carbohydrate digestion (Bisschoff, 1994; Patel et al., 2012). It is believed that alpha glucosidase 
inhibitors are saccharides that competitively inhibit carbohydrate hydrolyzing enzymes like alpha 
glucosidase and alpha amylase (Bischoff, 1995; Horii et al., 1986; kimet al., 1999).  
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Studies have shown that acarbose, a common alpha glucosidase inhibitor used in the treatment of 
T2D, improved metabolic state and also reduced blood glucose levels in diabetic animals, which 
subsequently reduced non-enzymatic glycation of protein and haemoglobin. These effects and 
further beneficial effects of acarbose against nephropathy, neuropathy, retinopathy, endothelial 
dysfunctions and CVD problems make it a potential therapy for prevention of T2D 
complications (Bischoff, 1995; Standl and Schnell, 2012). 
 
 
FIGURE 2.4: Non-systemic action of acarbose to delay carbohydrate absorption (Standl and 
Schnell, 2012). 
 
Furthermore, the effects of alpha glucosidase inhibitors on nutrient gastric emptying rate and 
gastrointestinal transit time have also been investigated in both diabetic and normal subjects. 
Kawaqishiet al.,(1997) and Hückinget al.,(2005) reported that acarbose and voglibose did not 
delay or alter the rate of gastric emptying in non-insulin dependent diabetic patients. However, in 
a study conducted by Ladas et al.,(1992) to investigate the effects of alpha glucosidase inhibitors 
on nutrient gastrointestinal transit time in normal subjects it was reported that 100mg of acarbose 
increased the rate of nutrient mouth to cecum transit time and the amount of carbohydrate 
reaching the colon by inducing mal-absorption of carbohydrate. Reduced absorption of nutrient 
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in a diet can facilitate movement of unabsorbed nutrient down the gastrointestinal tract and 
towards the large intestine, which can cause osmotic diarrhea in the colon. 
Nevertheless, the risk of development of adverse effects with the use of various hypoglycemic 
drugs is not an exception for alpha glucosidase inhibitors. It has been reported that treatment 
with acarbose was associated with abnormal increase in serum transaminase levels, which is an 
indicator for hepatotoxic effect of this drug; hence it is contra-indicated for patients with 
cirrhosis (Carlson, 2000). Oral hypoglycemic drugs are usually of synthetic origin and relatively 
expensive, and because of these and other adverse effects associated with these conventional 
chemically originated drugs, other therapeutic agents like some sugar substitutes have gained 
popularity in the management of diabetes, obesity and related diseases without sacrificing 
sweetness.  
 
2.6 Sugar Substitutes and Artificial Sweeteners 
Regular table sugar is normally used as a sweetener by most individuals and also in many 
consumables that contains mainly sucrose. Sucrose is a disaccharide that is rapidly digested and 
broken down into glucose and fructose by sucrase at the outer brush-border of the small intestine. 
It is contained in some fruits and vegetables, which however contributes relatively lesser 
amounts compared to that derived from table sugar and sucrose added to manufactured food 
(Southgate et al., 1978). Fructose and glucose resulting from sucrose digestionare equimolarin 
amount, although about 20% of the fructose may become converted to glucose before absorption 
(Brunzell, 1978; Nutall and Cannon, 1981). Glucose is rapidly absorbed via a mechanism of 
facilitated diffusion. For this reason, large consumption of sucrose has a direct and quick impact 
on blood glucose and subsequently on other metabolic parameters, which could be very 
detrimental for diabetic patients (Olefsky and Crapo, 1980). Furthermore, several studies have 
reported that detrimental positive balance in calorie and body weight, obesity as well as 
uncontrolled loss of body weight can be caused by over consumption of sucrose and other 
refined sugars (Harrington, 2008; Malik et al., 2006). 
Despite the detrimental effects associated with sugar consumption, the consumption and demand 
for sugar is still increasing. Supporting this, it was reported that between 2006 and 2008, the 
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global demand of sugar increased by about 3.5million tons (Deshpande and Jadad, 2008). The 
increasing mortality and morbidity rate associated with T2D and related diseases over the years 
have been a case of concern. In the 1980’s, both the Finnish Diabetes Association (FinDA) and 
the British Diabetes Association (BDA) recommended the continued restriction of sucrose and 
exclusion of rapidly absorbed mono- and disaccharides, except during emergency cases like 
hypoglycemia (BDA, 1982 and Huttunen et al., 1982). Howevre, the consumption of a modest 
amount of sucrose was regarded as acceptable, but may affect metabolic control (BDA, 1984).  
Artificial sweeteners (ASs) and sugar substitutes (SSs) have now become a replacement for 
regular table sugar or sucrose in the diet of most people, especially in diabetic and obese 
individuals. They have found increasing application in a wide range of products like table top 
sweeteners, baked products, syrups, candies, sweet toppings, beverages, pharmaceuticals, sugar 
free desserts etc, because of their beneficial effects like relatively higher or similar sweetness 
levels with little or negligible effect on postprandial glucose, serum insulin and caloric value 
compared to sucrose (Islam, 2011; Islam and Indarjit, 2012). 
Sugar substitutes, are substances that can be used to replace regular table sugar while giving 
about similar sweetness, and ASs are believed to be a group or class of SSs that are non-nutritive 
intense sweeteners of synthetic origin, although a few are derived from natural sources (Mayo 
clinic, 2010). Natural or nutritive sweeteners on the other hand are a second class of SSs that are 
majorly derived from natural source and have approximately same sweetness power as sucrose. 
Nevertheless, SSs are sometimes grouped into subclasses according to their calorie content: 
nutritive sweeteners provide energy with sweetness, while non-nutritive sweeteners are also 
sweet but do not provide energy (ADIA, 1998) 
 
 
2.6.1 Synthetic and Non-nutritive Sweeteners 
These groups of SSs are also called ASs, which are basically of synthetic origin. They are intense 
sweeteners with sweetness power ranging from 30 to 13,000 times sweeter than sucrose 
(Mayhew et al., 2003). They are known to offer consumers the taste of sweetness with little or no 
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calorie, and as such can help in weight gain and blood glucose control (ADIA, 1998). 
Furthermore, they are quite compatible with other food ingredients and relatively stable under 
different environments and conditions like heat. Their synergistic ability has allowed their 
combined use with other sweeteners to give a better blend of sweetness and sweetness 
powercompared to individual taste, and as such only a relatively very small amount of ASs are 
required to improve overall sweetness and taste (ADIA, 1998). These qualities have increased 
the popularity and use of ASs.  
Six ASs have been reported to be commonly used by overweight, obese and diabetic individuals, 
which include saccharin, aspartame, neotame, sucralose, acesulfame potassium (Ace-K) and 
stevia (Academy of Nutrition and Dietetics: AND, 2012;Islam and Indarjit, 2012). Theseare 
usedin a range of edible products like table top sweeteners, baked products and pharmaceuticals, 
and have been approved by the United States (US) Food and Drug Administration (FDA) as 
those that are safe for consumption, hence are now regarded as “Generally Regarded As Safe” 
(GRAS) with established Accepted Daily Intake (ADI) and Estimated Daily Intake (EDI) for 
each of them (AND, 2012). 
 
2.6.1.1 Saccharin 
Saccharin is the foremost ASs to be discovered and the oldest non-nutritive sweetener to gain 
approval for use in food and beverage (AND, 2012). Constantine Fahlberg, in 1897 accidentally 
discovered saccharin from O-methyl-benzenesulfonamide (OCBS),while working in Ira 
Remsem’s laboratory (DuBois, 2006). Rather than an expected O-carboxy-benzenesulfonamine 
compound, the oxidation of OCBS resulted in a novel heterocyclic compound (1,1-dioxo-1,2-
benzothiazol-3-one), also called saccharin. He accidentally spilled a chemical on his hand and 





FIGURE 2.5: Molecular structure of saccharin (DuBois, 2006). 
Saccharin is water soluble, heat stable and has some brand names like “Sweet N Low” and 
“Sugar Twin” (AND, 2012). It is about 200 to 700 times sweeter than sucrose and it is not 
metabolized in human (Mitchell and Pearson, 1991). However it is known to have a bitter after 
taste that is somewhat metallic. The good stability of saccharin at high temperatureallows it to 
retain its sweetness when used for cooking and baking. Furthermore, it is rapidly excreted in the 
feces and urine and also provides no energy, since it is not metabolized by the body (AND, 
2012).  
Saccharin has been used as a replacement for sugar for several decades and was originally added 
to the “GRAS” list. However, in 1970’s there were some controversies regarding the safety of 
saccharin consumption, because it has been reported that saccharin isassociated with the 
development of cancer of the bladder in laboratory rats. For this reason, the US FDA proposed a 
ban on the use of saccharin, but was replaced in the same year by an 18 months moratorium, 
which required product containing saccharin to carry the following warning: “Use of this product 
may hazardous to health. These products contain saccharin, which has been determined to cause 
cancer in laboratory animals” (ADIA, 1998). However, several studies on the use of saccharin, 
especially in higher users like diabetic individuals did not show or support the carcinogenicity of 
saccharin in human (Morgan and Wong, 1985; Rischet al., 1988). The mechanism behind the 
carcinogenicity of saccharin in rats was later determined by the National Institute for 
Environmental Health Science (NIEHS) to be irrelevant to human beings but may however 
increase the risk of adverse effect for sub groups like heavy smokers. 
In 1991, the proposed ban of saccharin was formerly removed by the US FDA and in 2000 the 
warning label requirement for products containing saccharin was formerly repealed (ADIA, 
1998; AND, 2012). Today saccharin is widely used in various products like canned fruits, 
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reduced calorie syrup, sweet toppings, baked foods, pharmaceuticals, beverages and chewing 
gums, and often used in combination with other sweeteners. The Academy of Nutrition and 
Dietetics, reported in 2012 that no ADI was presently determined for saccharin. However, an 
EDI of 0.1 to 2mg per kg body weight has been determined for average and higher users 
(Neltneret al., 2011; Renwick, 2006). 
 
2.6.1.2 Aspartame 
Aspartame was discovered accidentally in 1965 by James M. Schlatter (AND, 2012). In an 
attempt to generate gastrin hormone (a tripeptide) for anti-ulcer assessment, an intermediate 
product (an aspartyl-phenylalanine methyl ester) was produced, which he accidentally noticed 
had a sweet taste and later named it aspartame. 
Aspartame is a non-saccharide sweetener. It is a methyl ester of aspartic acid and phenylalanine 
dipepetide that is about 160 to 200 times sweeter than sucrose, and has other brand names such 
as “Nutra Sweet” and “Equal” (ADIA, 1998). Aspartame is not suitable for cooking or baking, 
since it is relatively unstable under high temperature and pH(Magnuson et al., 2007). It is 
however encapsulated to increase its heat stability and also extend its use in some commercially 
baked products (ADIA, 1998).  
 
 
                      FIGURE 2.6: Molecular structure of aspartame (Ager et al., 1998). 
 
Aspartame, like most peptides is hydrolysable to produce constituent amino acids. In the 
intestine, aspartame is hydrolyzed by intestinal esterases to give aspartic acid methanol and 
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phenylalanine (Magnuson et al., 2007). The amino acids resulting from its hydrolysis can be 
further metabolized to provide 4kcal/g of energy (Ager et al., 1998). However, because of the 
intense sweetness of aspartame, only a small amount is needed to provide required sweetness, 
thus only a negligible amount of energy is derived from aspartame.  
It has been reported that formaldehyde and formic acid can also be formed from the metabolism 
of aspartame, which have been found to be the cause of negative side effects such as headache, 
memory loss, joint pains, muscle sparsm, dizziness, fatigue, vision problem, asthma or chest 
tightness, rashes and weight gain (Dyar, 2008). Diketopiperazine is another toxic product that 
can result from the breakdown of aspartame when exposed to heat (ADIA, 1998). However, 
reports from animal toxicity studies have shown that the small amounts of aspartame used in 
beverages cannot produce a toxic amount of diketopiperazin (FDA, 1983). Also, in 1995, the US 
department of health and human services (HHS) reported some cases of persons who complained 
of allergic reactions like edema of the lips, tongue and throat; skin reactions; and respiratory 
problems after consumption of aspartame, although when investigated under controlled 
experimental conditions, aspartame was not able to produce similar allergic reactions in the same 
individuals (Garrigaet al., 1991; Gehaet al., 1993). 
Furthermore, because aspartame is hydrolyzed in the intestine to yield aspartic acid and 
phenylalanine, it is advised that people with the rare hereditary disease, phenylketonuria (PKU) 
should consume products containing aspartame with caution. Infact, the FDA requires that food 
containing aspartame should carry the following label: “Phenylketonurics: contains 
phenylalaninine” (AND, 2012). Phenylketonuria is a rare homozygous recessive in-borne error 
of metabolism, in which sufferers are unable to metabolize phenylalanine (ADIA, 1998); and as 
such, when such people consumephenylalanine, it causes increased plasma levels of 
phenylalanine (Stegink and Filer, 1996), deranged monoamine neurotransmitters synthesis 
(Maher and Wurtman, 1987) and adverse effects (Wolf-Novak et al., 1990). 
In 1981 and 1983, aspartame received approval by the FDA to be used in specific foods and soft 
drinks respectively, and in 1996, it gained approval as a general use sweetener (AND, 2012). It is 
presently used in more than 6000 products marketed around the world, including diet sodas, 
sugar-free yogurts, ice-cream, chewing gums, gelatin powder etc. However, despite the use of 
aspartame in numerous products, the average consumption for highest users still remains below 
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the recommended ADI (Magnuson et al., 2007; Renwick, 2006). The recommended ADI and 
EDI of aspartame are about 50mg/kg body weight and 0.2 to 4.1mg/kg body weight respectively 
(Magnuson et al., 2007). 
 
2.6.1.3 Sucralose 
Sucralose (trichlorogalactosucrose) is a halogenated disaccharide sweetener, in which three 
hydroxyl groups in the sucrose molecule are replaced by three chlorine atoms (Ager et al., 1998; 
Grotz and Munro, 2009). It was accidentally discovered in 1976, while testing for halogenated 
sugar in a British sugar company called Tate and Lyle (Molinary and Quinlan, 2006). 
 
 
             FIGURE 2.7: Molecular structure of sucralose (Molinary and Quinlan, 2006). 
 
Sucralose is about 600 times sweeter than sucrose, heat stable and suitable for cooking and 
baking (ADIA, 1998). It has brand names like “Splenda” and “Sucra Plus”. Although sucralose 
is synthesized from sucrose, a rapidly digested and absorbed sugar, it is not rapidly metabolized 
or absorbed in the body (ADIA, 1998;Molinary and Quinlan, 2006). In fact, AND(2012) 
reported that about 85% of ingested sucralose is not absorbed by the body, but excreted in the 
urine and feces unchanged. 
The FDA approved sucralose in 1998 as a table top sweetener and also for use in some products 
like non-alcoholic beverages, desserts and some confections after several review of so many 
studies in human and experimental animals, which concluded that sucralose is not associated 
with any risk of cancer and reproductive or neurologic problems (ADIA, 1998). Presently, 
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sucralose has an FDA approved ADI and EDI of 5mg/kg body weight and 0.1 to 2.0mg/kg body 
weight respectively, and is used in common products like baked foods, reduced calorie yogurts, 
canned fruits, flavored creamers etc (AND, 2012). 
 
2.6.1.4 Neotame 
Neotame is chemically named N-{N-(3,3-dimethylbutyl)-L-2-aspartyl}-L-phenylalanine 1-
methyl ester. Like aspartame, it is a derivative of the dipeptide of phenylalanine and aspartic acid 
(AND, 2012). After a long term research that was aimed at discovering a high intensity 
sweetener with good performance and safety qualities, Claude Nefre and Jean Marie developed 
neotame (Witt, 1999). Althoughneotame is a modified form of aspartame, it however differs 
from aspartame due to the presence of a neohexyl group and an extended 3,3-dimethyl butyl 
group that is attached to the amino group of aspartic acid moiety (Indarjit, 2011; Witt, 1999). It is 
believed that the extended 3,3-dimethylbutyl moiety in neotame inhibits the hydrolysis of the 
dipeptide unit into aspartic acid and phenylalanine by inhibiting peptidase action (Mayhew et al., 
2003). Neotame is therefore considered to be safe for consumption even by sufferers of PKU. 
 
 
FIGURE 2.8: Molecular structure of neotame (O’Donnell, 2006). 
 
Neotame is about 30 to 60 times and 7,000 to 13,000 times sweeter than aspartame and sucrose 
respectively and also possesses excellent stability (AND, 2012; Witt, 1999). Witt(1999) further 
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reported the presence of an N-alkyl function in neotame molecule, which prevents the formation 
of diketopiperazine products. This quality of neotame and its inertness to some food components 
like flavoring agents and reducing sugars is responsible for its excellent stability, which is useful 
in baking and cooking. However, the stability of neotame can vary with pH in aqueous 
conditions and also with storage conditions (Nofri and Tinti, 2002). 
Although neotame is absorbed partially in the intestine, it is however rapidly metabolized by 
esterases in the body to produce equimolar amounts of de-esterified neotame and methanol 
(O’Donnell, 2006). The de-esterified neotame is rapidly excreted in the urine and feces, while 
the amount of methanol produced is very insignificant, thus making it a safe non-caloric 
sweetener (Norfri and Tinti, 2002). Furthermore, the amount of phenylalanine from neotame that 
is released into the body is very negligible, since very little amount of neotameis needed to 
achieve sweetness. 
Neotame was approved by the FDA in 2002 as a general use sweetener with an ADI and EDI of 
18mg/kg body weight and 0.05 to 0.17mg/kg body weight. Nevertheless, neotame to date is 
rarely used in foods (AND, 2012). It is however contained in products like sugar free beverages, 
chewing gums, soft drinks, jams, baked food etc.  
 
2.6.1.5 Acesulfame Potassium (Ace-K) 
The discovery and development of acesulfame potassium (Ace-K) was possible, because of the 
prior discovery of oxathiazonedioxides (OTZDs). It was observed that most methyl and ethyl 
substitute OTZDs have sweet tastes, and among this group of organic acids, Ace-K was found to 
have pure sweet taste compared to others (Ager et al., 1998). 
Ace-K is a combination of an organic acid and potassium that is water soluble and non-toxic. It 
has other brand names like “Sunnet”, “Ace-K” and “Sweet One”. Ace-K is about 200 times 
sweeter than sucrose, and is commonly used in combination with other non-nutritive sweeteners 
(NNSs) in different products (AND, 2012). It combines well with other NNSs to cause a 
sweetness synergy that will result in a better sweet taste (AND, 2012; Haber et al., 2006). It is 





FIGURE 2.9: Molecular structure of acesulfame-K (Harber et al., 2006). 
 
Ace-K is not metabolized in the body on ingestion, and about 75% is excreted in the urine and 
feces chemically unchanged; thus, it provides no energy or calorie to the body (Renwick, 
1986).The International Food Information Council Foundation (IFICF) in 1998 reported that 
over 90 different studies on the safety of Ace-k consumption have indicated that it is not linked 
to any major life threatening ailment, and it is safe for consumption by any group of individual. 
According to them, even the amount of potassium derived from Ace-K (about 10mg per ADI) 
compared to about 2000mg to 3000mg obtained daily from fruits and food consumption is quite 
negligible to cause any health problem. 
Ace-K was approved by FDA in 1998 as a table top sweetener and for use in foods and 
beverages, and in 2003, as a general use sweetener with an ADI and EDI of 15mg/kg body 
weight and 0.2 to 1.7mg/kg body weight (AND, 2012). It is used in products like baked foods, 
chewing gums, syrups, sweet toppings sugar free and frozen desserts etc. 
 
2.6.1.6 Stevia 
This sweetener comprises of some extracts from the leaves of the plant Stevia 
rebaudianabertoni, first botanically described in 1899 by a botanist M. S. Bertoni as a sweet 
perennial herb that was native to South America (Thomas and Glade, 2010). Stevia plant has 
been for long used to enhance taste of tea and medicinal portion or even chewed because of its 
sweet taste. However, after stevia plant became popularly known for its sweet leaf, it has been 
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cultivated in China, South East Asia and India, which are some of the major cultivators of Stevia 
plant in the international market (Mishra, 2011). 
 
 
FIGURE 2.10: Stevia rebaudianaplant (Rajesh et al., 2010). 
 
Stevia is believed to bethe major high intensity and non-nutritive sweetener that is non-synthetic 
and naturally sourced (Megediet al., 2005;Soejarto et al., 1983). Stevia leaf contains several 
extract that are believed to be the cause of its sweet taste. These extracts contain some sweet 
tasting diterpenoid glycosides, including steviosides, rebaudioside(reb) A, B, C, D and E, 
dulcoside, steviobioside, Isosteviol and dehydroisosteviol, which have sweetness power ranging 
from 50 to 450 times compared to sucrose (Chatsudthipong, 2009). These diterpenoid glycosides 
share a common steviolaglycone backbone, but differ in their carbohydrate residue at carbon-13 
and -19, which is believed to be the cause of their relatively different sweetness power 
(Chatsudthipong, 2009). Steviol glycosides are shelf and heat stable, suitable for cooking and 
baking, and also possess clean sweet taste, but may be bitter at higher amounts (Goyalet al., 
2010;Prakashet al., 2008). 
The adverse health issues associated with other synthetic NNSs greatly influenced the popularity 
and use of stevia. For instance, the marketing of steviosides in Japan began in the 1970’s, when 
chemically synthesized sweeteners were banned from use (Thomas and Glade, 2010). Since then, 
stevia plant has been cultivated and used in other places including the US, Canada and Europe 
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(Chatsudthipong, 2009). Furthermore, even some recent studies have shown that stevia plant 




FIGURE 2.11: Chemical structures of the main S. rebaudiana sweeteners and their 
aglyconsteviol (Gardana et al., 2003). 
 
Among the steviol glycosides, reb A became the first to be approved as GRAS in 2008, which 
was then followed by stevioside (AND, 2012). Furthermore, in 2009, the French government 
approved the use of stevia extract consisting of at least 97% rebA in food and beverages 
(Thomas and Glade, 2010). Today, the respective ADI and EDI of 4mg to 5mg/kg body weight 
and 1.3mg to 3.4mg/kg body weight have been set for steviosides, reb A and other steviol 
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glycosides (AND, 2012; Thomas and Glade, 2010). They are used in several food products like 
cereals, table top sweeteners, beverages, energy bars etc. 
Despite the wide application of artificial or synthetic sweeteners, the health issues associated 
with their consumption still remains a concern to most people. Some recent studies have reported 
life threatening side effects that are caused by short- or long-term consumption of most 
chemically synthesized sweeteners. Saccharin have been reported to have carcinogenic effects on 
both human and experimental animals (Bell et al., 2002; Cohen, 2001), although this is still a 
controversy (Abergaz, 2007; Huff and LaDou, 2007). 
Aspartame has been reported to cause bladder and brain cancer, chronic fatigue, leukemia, 
lymphomas and some genetic disease (Whitehouse et al., 2008). It has also been reported that 
aspartame can be responsible for fibromyalgia, gastric and pancreatic cancer as well as reduction 
of anti-oxidant status of the liver (Abhilashet al., 2011; Bosettiet al., 2009; Ciappucciniet al., 
2010). As previously stated, aspartame can form toxic substances like formaldehyde, which have 
been found to cause several negative side effects (Dyar, 2008; Gilliet al., 2008; Jacob and 
Stechschuite, 2008). Furthermore, the fact that phenylalanine is a major product from aspartame 
breakdown is also a serious problem to individuals suffering from PKU, who cannot metabolize 
phenylalanine. 
Furthermore, sucralose has been reported to adversely affect microflora in the gastroinstestinal 
tract and cause inflammatory disease of the bowel (Brusicket al., 2009; Qin, 2011). In fact, a 
recent study reported that twelve week daily consumption of 5mg/kg body weight of sucralose 
reduced the beneficial fecal microflora amounts and adversely alters the expression levels of 
some drug metabolizing factor (Abou-Doniaet al., 2008). A number of studies have also reported 
that sucralose can trigger migraine and headaches (Grotoz, 2008; Hirsch, 2007; Patel et al., 
2006). However, these adverse effects of sucralose are still a subject of debate (Brusicket al., 
2009; Gortz and Munro, 2009). 
Furthermore, Ace-K has also been reported to be linked to some health problems. Although the 
total toxicity profile of Ace-k is still yet to be studied (Karstadt, 2010), recent genotoxicity study 
reported that more DNA damage in albino mice was observed when fed with 150mg to 
160mg/kg body weight of Ace-K than when fed with aspartame (Bandyopudhyayet al., 2008). 
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Other than these adverse health issues that have been reported to be associated with the 
consumption of these chemically synthesized sweeteners, human beings will prefer natural 
products, in spite of their search for a sugar replacer. Although they have some calorie content 
and are less sweet compared to chemically synthesized sweeteners, natural sweeteners such as 
honey, fructose, molasses, high fructose corn syrup, malpe syrup and sugar alcohols have 
become a preferred sugar replacement in these contexts (Islam and Indarjit, 2012). 
 
2.6.2 Natural and Nutritive Sweeteners 
Most natural sweeteners are nutritive and produce calorie, although some of them can also be 
refined and are not naturally sourced. These refined nutritive sweeteners are also referred to as 
added sugar and are contained in processed food (ADIA, 1998; AND, 2012). Natural and 
nutritive sweeteners include cane juice, fruit juice concentrate, honey, glucose, liquid fructose, 
fruit nectar, crystal dextrose, high fructose corn syrup (HFCS), maple syrup, molasses and sugar 
alcohols. 
Sucrose, glucose and fructose are the primary nutritive sweeteners that occur naturally in food 
like honey or added as sugars, like in syrups. These sweeteners are present in corn syrups (maple 
and molasses syrups), pancake syrup, plant nectar, honey and HFCS. HFCS is majorly glucose 
produced from corn syrup. It is first processed enzymatically to increase its fructose content and 
then mixed with glucose to contain about 42% to 55% of fructose (AND, 2012). Agave nectar, 
which is produced from the Agave plant, Agave tequilana (Phillips et al., 2009) is another 
natural sweetener that some consumers have shown interest on. Inulin, a fructant present in 
freshly extracted Agave juice is converted enzymatically from a complex carbohydrate to simple 
monosaccharide, which contains mostly fructose and some amounts of dextrose and glucose 
(Cedeno, 1995;Mancilla-Matgalli and Lopez, 2002). 
D-tagatose isanother ketohexose nutritive sweetener used in food. D-tagatose is an epimer of D-
fructose, which differs from fructose, because of the opposite orientation of the hydroxyl and 
hydrogen groups at carbon-four (AND, 2012; WHO, 2005). Ithas been identified in gum exudate 
of cacao tree, but it is obtained from D-galactose by an enzyme-catalyzed isomerization reaction 
(WHO, 2005). It has similar appearance, texture and sweetness as sucrose but produces lesser 
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calorie and enhances low postprandial glucose (Levin et al., 1995; Livesey and Brown, 1996).D-
tagatose is used with other sweeteners in food as a sweetness synergizer, texturizer, stabilizer, 
humectants, and flavor enhancer. 
These nutritive sweeteners improve the functional properties like sensory (e.g. taste), physical 
(e.g. viscosity), microbial (e.g. preservation) and chemical (e.g. anti-oxidation) characteristics of 
the food in which they are present (Davis, 1995). They afford approximately similar sweetness, 
but produce lesser amount of energy or caloriecompared to regular table sugar or sucrose. 
Furthermore, their poor absorption and rapid removal from the blood (for example fructose) can 
also improve glycemic control than sucrose or sucrose based sweeteners (Uusitupa, 1994). 
However, it has been reported that the chronic or over-consumption of the above-
mentionednatural nutritive sweeteners may cause severe health problems such as gastrointestinal 
discomforts, over-weight, hypertension, obesity, T2D, cardiovascular diseases and other 
diseases related to metabolic syndrome (ADIA, 1998; AND, 2012; Islam and Indarjit, 2012; 
Stanhope, 2011). Although not consistently observed (Truswell, 1994), high fructose intake can 
increase lipid precursorsproduction and risk of hypertriglyceridemia (ADIA, 1998). 
Furthermore, a parallel rise in obesity, diabetes and hypertension have been witnessed for the 
past thirty years with fructose consumption (Johnson et al., 2007; Segal et al., 2007), and 
several studies have reported that fructose can induce insulin resistance, hyperlipidemia, high 
blood pressure, oxidative stress, endothelial dysfunction, glomerular hypertension, renal injury 
and fatty liver disease (Brown et al., 2008;Ouyanget al., 2005;Sanchez-Lozadaet al., 2008).  
On the other hand, sugar alcohols or polyols are preferred sugar substitutes compared to other 
natural and artificial sweeteners, because they offer less calorie; other potential health benefits 
like reduced glycemic response; and less health harzards and risk of dental caries (ADIA, 1998; 
Islam, 2011). 
 
2.6.3 Polyols or Sugar Alcohols 
Sugar alcohols (SAs) can be referred to as sugar replacers, because they are usually used 
insteadof sugar or sweeteners (McNutt and Sentki, 1996). Most of them occur naturally in plant 
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products like fruits and berries; although commercially, they are not naturally sourced but 
synthesized. Commercially synthesized sugar alcohols are mostly produced by hydrogenation of 
their corresponding carbohydrate precursors to form a distinct compound that is neither a sugar 
nor an alcohol. They differ from their carbohydrate precursors, because of the presence of a 
Hydroxyl group (-OH), which replaces the aldehyde (-CHO) or carbonyl (-C=O) functional 
group of the aldose and ketose moiety of their carbohydrate precursors. 
Polyols or SAs have been used for long in several food products in order to reduce carbohydrate 
intake that can cause blood glucose rise. Some of them are often used in combination with other 
sweeteners, because of their bulking properties, hence are referred to as bulk sweeteners (AND, 
2012; Dills, 1989). Most of them are slowly and partially absorbed in the small intestine by 
passive diffusion, while the remaining are metabolized indirectly via fermentative degradation by 
intestinal flora to produce short-chain fatty acids, which are further metabolized to produce 
energy (ADIA, 1998; Oku and Nakamura, 2002).  
Assuming polyols are completely absorbed, direct metabolism will produce about 4 kcal/g of 
energy like simple sugars. However, since they are only partially absorbed and indirectly 
metabolized, they provide lesser energy, hence are referred to as low-energy sweeteners. 
Nevertheless, the energy provided by different polyols varies because of their difference in 
digestibility, absorption and metabolism (AND, 2012). Furthermore, the incomplete absorption 
and indirect metabolism of polyols translates into only a small rise in blood glucose, hence they 
elicit low glycemic effects and insulinenic response. These beneficial properties have made them 
potential therapeutic substances for managing diabetes, obesity and metabolic syndrome. 
However, most polyols can also cause some side effects like bloating, flatulence, abdominal 
pains and diarrhea when over-consumed, which is believed to be caused by excess unabsorbed 
polyols reaching the large intestine (ADIA, 1998; Islam, 2011). Nevertheless, SAs are widely 
used to produce products like chewing gums, baked food, candies, pharmaceuticals, frozen 
desserts and yoghurts, table top sweeteners etc. Some widely used SAs, presently in use include 









Mannitol is a sugar alcohol that occurs naturally in pineapples, olives, sweet potatoes and 
carrots. It appears as a white crystalline substance. Its structure is an optical isomer of sorbitol, 
with opposite orientations of their hydrogen and hydroxyl group on carbon number two in the 
carbon back bone of the structure (Figure 2.13). It is typically produced by hydrogenation of 
fructose (a ketose sugar) derived from starch or sugar (Kearsley and Deis, 2006). It is however 
commercially extracted in China from a certain species of seaweed. The caloric value of 
mannitol is 1.6kcal/g and it is about 50% as sweet as sucrose, and also possesses a taste 
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characterized by a desired cooling effect, often used to mask bitter taste (Kearsley and Deis, 
2006;Stowell, 2006). 
It has been reported that only about 25% of ingested mannitol is absorbed in the small intestine 
(Indarjit, 2011). The undigested and unabsorbed portion becomes fermented in the large intestine 
by colonic bacteria to produce short-chain fatty acid that is metabolized to produce energy. A 
concomitant release of gases during fermentation may cause abdominal discomforts like pains, 
boating and flatulence. Mannitol is used for producing products like baked food, 
pharmaceuticals, candies, chewing gums, chocolates etc. 
 
2.6.3.2 Sorbitol 
Being an isomer of mannitol, it is typically produced from the hydrogenation of glucose, an 
aldose sugar (Kearsely and Deis, 2006). Sorbitol is found naturally in fruits like apples, pears and 
plums. With a much more cooling effect than mannitol, sorbitol is about 50% to 60% as sweet as 
sucrose, and is generally considered as a bulk sweetener (Kearsely and Deis, 2006; Stowell, 
2006).  
Like most sugar alcohols, sorbitol is partially digested and absorbed by the body hence possess 
the tendency of causing abdominal discomforts. The caloric value of sorbitol is about 2.6kcal/g, 
and is contained in products like candies, pharmaceutical products, chewing gums, baked food 
and frozen desserts (Kearsely and Deis, 2006). 
 
2.6.3.3 Erythritol 
In the course of a research project initiated by Cerestar to produce different types of polyols, 
using fermentation process, a strain of yeast was observed to produce erythritol in significant 
amounts (Perko and DeCock, 2006). Subsequent research showed that erythritol possesses 
approximately zero caloric value and high digestive tolerance compared to other sugar alcohols 
(Perko and DeCock, 2006). 
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Erythritol is a four carbon sugar alcohol with an anhydrous crystalline white appearance, and a 
granular texture similar to sucrose.  Although it is rapidly absorbed in the small intestine, it 
cannot be metabolized by the body and it is subsequently absorbed in the kidney and then 
excreted in the urine and feces, thus contributes no caloriewith relatively minimal abdominal 
discomfort. This quality makes it very useful for diabetic and obese individuals. 
Like most sugar alcohols erythritol is a bulk sweetenerwith 60% to 70% sweetness compared to 
sucrose and it possesses an after taste cooling effect when actively dissolving (Perko and 
DeCock, 2006). It is contained in products like beverages, chewing gums, chocolates, candies, 
fondants, lozenges and baked food etc. 
 
2.6.3.4 Lactitol 
After the discovery of lactitol in 1920 by J. B. Senderens,a French food chemist, it has been 
produce by the catalytic hydrogenation of lactose using nickel as a catalyst (Young, 2006). It is a 
disaccharide sugar alcohol that is composed of sorbitol and galactose. Lactitol is a white 
crystalline powder with high purity and mild sweet taste that resembles the taste profile of 
sucrose without any after taste and it is only 40% as sweet as sucrose (Stowell, 2006; Young, 
2006). 
Once ingested, only about 2% of lactitol is absorbed in the small intestine by passive diffusion, 
while the undigested portion is fermented in the large intestine and metabolized for energy 
production. For this reason it has high tendencies of causing abdominal discomforts (Young, 
2006). It has been reported that only about 2kcal/g of energy is produced from ingested lactitol, 
without causing any rise in blood glucose level, thus making it suitable for diabetic and obese 
people (Stowell, 2006; Young, 2006). Lactitol is contained in products like chocolates, baked 







Like sorbitol and mannitol, maltitol is classified into the sugar alcohol group known as 
hydrogenated starch hydrolysates (HSH). Maltitol is produced from starch by hydrolysis and 
catalytic hydrogenation (Kearsley and Deis, 2006). Essentially it is the product obtained from 
hydrogenation of maltose sugar. Maltitol is a disaccharide that is composed of glucose and 
sorbitol units. 
It shears similar properties with sucrose, and it is about 70% as sweet as sucrose (Kearsley and 
Deis, 2006;Stowell, 2006). Like most sugar alcohols,maltitol is partially digested, absorbed and 
metabolized in the body, providing only about 2.4kcal/g of energy (Kearsley and Deis, 2006). 
Maltitol is used to produce products like chocolates, caramels, baked food, and some dairy 
products like yoghurts and flavored milk etc. 
 
2.6.3.6 Xylitol 
Xylitol is a five carbon polyol that was first discovered in 1891 by Emil Fischer, a German 
chemist, who later reported this discovery in the same year (Bond and Dunning, 2006).  Usually 
less than 1%, xylitol is known to occur naturally in many fruits and vegetables such as yellow 
plums, strawberries, raspberries, spinach, lettuce, onion, carrots etc (Bond and Dunning, 2006; 
Mäkinen and Söderling, 1980). 
However, with the progress in research, researchers discovered the feasibility of deriving xylitol 
from xylose, which became a major success in the production of xylitol. Xylose is mostly 
produced from xylan (a polymer of xylose), which is contained in hemicelluloses sources like 
wood chips and corn-cobs (Bond and Dunning, 2006). Xylose is subsequently converted to 
xylitol by a catalytic hydrogenation process. Further crystallization, centrifugation and drying 





FIGURE 2.13: Outline method for manufacture of xylitol (Bond and Dunning, 2006). 
 
Xylitol appears as a white crystalline solid. It is almost as sweet as sucrose (Stowell, 2006) and 
gives a taste that is characterized by an after cooling effect void of any bitter after taste; hence it 
is popularly used in chewing gums (Pierini, 2012). Xylitol is often used in combination with 
sorbitol and manitol to produce unique sweetness synergy that will enhance its taste (Bond and 
Dunning, 2006).  
Like most sugar alcohols, xylitol is partially and slowly absorbed in the small intestine by 
passive diffusion. It is reported that only about 25% to 50% of ingested xylitol is digested and 
absorbed while about 50% to 75% reaches to the large intestine where they are fermented by 
colonic bacteria to short-chain fatty acids, which is further metabolized for energy production 
(Bond and Dunning, 2006). Once digested and absorbed, xylitol is withdrawn into the liver, 
where it becomes part of normal carbohydrate metabolism via the glucoronic acid-pentose 




FIGURE 2.14: Glucuronic acid – pentose phosphate shunt. Path-way showing the link between 
xylitol metabolism (red) and glucuronic acid – pentose phosphate shunt (black) (Bond and 
Dunning, 2006). 
 
On the other hand, the fermentation of the undigested and unabsorbed portion of the ingested 
xylitol by colonic bacteria produces gases such as methane hydrogen and carbon dioxide which 
is responsible for abdominal discomforts like bloating, flatulence and abdominal pains. 
Furthermore, organic acids resulting from this fermentation process can draw water into the 
colon via osmosis, which can lead to diarrhea. High quantities of xylitol consumption, over 50g 
may promote these negative side effects (Bond and Dunning, 2006). However, tolerance ability 
of xylitol is varied from person to persons. 
Despite these few side effects resulting from xylitol consumption, its beneficialeffects cannot be 
over emphasized. Reports from acidogenicity studies have consistently shown that xylitol cannot 
be fermented by oral bacteria to produce acid that can cause dental problem like caries 
development, plaque formation, damaged oral cavities and tooth decay; hence xylitol is referred 
as being non-acidogenic and non-cariogenic in nature (Bär, 1988). Its ability to completely halt 
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the progression of caries has promoted its inclusion in oral care products like tooth paste, mouth 
wash and sugar-free chewing gums (Indarjit, 2011). 
Furthermore, another added facet to xylitol’s benefit is its suitability for diabetic and obese 
individuals. The passive and incomplete digestion and absorption of ingested xylitol results in 
only a small rise in blood glucose that is very insignificant when compared to a similar effect 
produced by an equivalent amount of sucrose (Bond and Dunning, 2006). This relatively low 
glycemic index of 13 and the consequent significantly low insulinemic response are important 
qualities for diabetic consumers. Also the slow and passive absorption of digested xylitol 
translates into a relatively low caloric value of about 2.5kcal/g (Islam, 2011). This value 
correlates with the fact that only about 60% of ingested xylitol is effectively metabolized to 
produce energy, whether through absorption or fermentation (Bond and Dunning, 
2006).Supporting this fact, previous studies have reported that xylitol can be a better sweetener 
than sucrose to manage obesity, diabetes and related metabolic problems and maintain diabetes -
related parameters at a physiologically safer and stable condition (Amoet al., 2011; Islam, 2011; 
Kishore et al., 2012). 
In a recent study, the in vivo anti-diabetic effect of xylitol has been reported as well (Islam and 
Indarjit, 2012). In this study, xylitol significantly reduced food and fluid intake, serum lipids, 
serum fructosamine, and non-fasting blood glucose; significantly increased serum insulin; and 
also improved most diabetes-related metabolic parameters in a T2D rat model.In this study, 
Islam and Indarjit (2012) speculated that xylitol consumption significantly prolonged gastric 
emptying, decreases food intake and accelerates intestinal transit of nutrients compared to 
glucose in normal human and experimental animals. This was demonstrated in his study, where 
lower food and fluid intake were reported in rats fed with 10% xylitol solution compared to the 
diabetic control. Faster intestinal transit reduces the rate of intestinal nutrient absorption and vice 
versa. We propose that xylitol may have delayed intestinal absorption of glucose or prevented 
the digestion of carbohydrate by digestive enzymes such as alpha glucosidase and alpha amylase, 
thus lowering NFBG and reducing food intake compared to diabetic control rats. 
Furthermore, as mentioned above, insulin plays a significant role in the cell uptake of circulating 
glucose. We also propose that the insulinotropic effect of xylitol, as reported by Islam and 
Indarjit (2012) may contribute to improving circulating glucose uptake, especially in muscle and 
44 
 
fat cells, hence improved the hyperglycemic condition of the diabetic rats. The above stated 
mechanisms are possible ways through which xylitol may improve hyperglycemia and anti-
diabetic conditions in T2D model of rats. However, studies on the mechanism(s) behind the anti-
diabetic effects of xylitol have not been done, especially under diabetic conditions. The present 
study was therefore aimed at investigating the possible mechanism(s) behind the anti-diabetic 
effects of xylitol, through the investigation of possible inhibitory effects of xylitol on 
carbohydrate digestion and glucose absorption under diabetic conditionsas well as the effects of 
xylitol on ex vivomuscle glucose uptake.Considering the wide application and use of xylitol, this 
study may open up new therapeutic approaches for diabetes and related metabolic disorders that 
are relatively affordable and void of the numerous side effects associated with most conventional 



































3.1 Chemicals and reagents 
Alpha amylase, alpha glucosidase, streptozotocin, 3,5-dinitrosalicylic acid, di-basic sodium 
phosphate, paranitrophenyl-α-D-glucopyranoside, acarbose, and citric acid were purchased from 
Sigma Aldrich, Germany. 
Mono-basic sodium phosphate, sodium hydroxide, sodium bicarbonate, sodium chloride, 
potassium chloride, calcium chloride di-hydrate, mono-basic potassium phosphate, magnesium 
sulphate, sodium hydrogen carbonate, phenol red, sodium citrate and sodium potassium tartrate 
were purchased from Merck, South Africa. 
Starch, glucose and fructose were purchased from Associated Chemical Enterprise, South Africa, 
while metformin and NOVO rapid insulin were purchased from a local pharmacy store in South 
Africa. 
 
3.2 In vitro study 
3.2.1 Measurement of In vitro Inhibition of α-amylase Activity  
The aim of this assay was to determine possible inhibitory effects of xylitol on α-amylase 
activity in the hydrolysis of starch. This was determined using methods modified from Mohamed 
et al., 2012. The principle of this assay was based on the fact that reducing sugars resulting from 
starch hydrolysis by α-amylase enzyme can reduce yellow 3,5-dinitrosalicylic acid (DNSA) to a 
reddish-brown 3 –amino-5-nitrosalicylic acid (ANSA), which absorbs light at 540nm. 
 
3.2.1.1 Preparation of Reagents 
Preparation of 500 mL of assay buffer (20 mM sodium phosphate buffer, pH 6.9): This was 
prepared as follows: 
A 500 mL of 20 mM mono-basic sodium phosphate solution was prepared by dissolving a 





A 500 mL of 20 mM dibasic sodium phosphate solution was prepared by dissolving a 1.4156 g 
of dibasic sodium phosphate (M.W., 141.56 g/mol) in 500 mL of dH2O 
 
A 20 mM mono-basic sodium phosphate solution was steadily added to 20 mM dibasic sodium 
phosphate solution, while stirring until a pH of 6.9 was attained 
 
This was stored in the refrigerator (4-8 OC) until further use. 
 
Preparation of 100 mL of 0.4 M sodium hydroxide (NaOH) solution: This was prepared by dissolving 
1.6 g of NaOH (M.W., 40 g/mol) in 100 mL of dH2O. 
Preparation of 100 mL of Dinitrosalicylic (DNSA) reagent: This was prepared by using heat 
to dissolve 1 g of DNSA (M.W., 228.12g/mol) and 30 g of sodium potassium tartrate (M.W., 
282.1 g/mol) in 100 mL of 0.4M NaOH. 
Preparation of 25 mL of 4 U/mL of α-amylase solution: This was prepared by 7.675 mg of 
porcine pancreatic α-amylase (1 mg ≡ 13 U) in 25 mL of assay buffer. 
Preparation of 50 mL each of 2.5%, 5%, 10%, 20%, 30% and 40% w/v xylitol solutions: 
This was prepared by dissolving 1.25 g, 2.5 g, 5 g, 10 g, 15 g and 20 g of xylitol in 50 mL of 
assay buffer respectively. 
Preparation of 50 mL of 1% starch solution: This was prepared by dissolving 0.5 g of starch 
in 50 mL of assay buffer. 
 
3.2.1.2 Assay Procedure 
Assay procedure was performed in triplicates as described in the following flow chart: 
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A 1 mL of sample (2.5% - 40% w/v xylitol solutions) or 1 mL of assay buffer (for control) and 1 
mL of 4 U/mL α-amylase solution or 2 mL of assay buffer for blank was added into a test tube, 
and incubated for 30 min at 37 OC after mixing well 
 
A 1 mL of 1% starch solution was added and the mixture was incubated for 1 hour at 37 OC 
 
A 1 mL of DNSA reagent was then added and the mixture was boiled for 10 min 
 
The mixture was allowed to cool and absorbance was read at 540 nm using a UV mini-1240 
Spectrophotometer (Shimadzu, Japan). 
 
3.2.1.3 Calculation of Percentage Inhibition of α-Amylase Enzyme Activity 
Percentage inhibition was calculated using the following formula: 
% Inhibition =  [(AbsC – AbsS)/ AbsC]  x 100  
Where, “AbsC” and “AbsS” mean absorbance of control and samples at 540 nm respectively. 
 
3.2.2 Measurement of In vitro Alpha-Glucosidase Activity Inhibition 
The aim of this assay was to determine the possible inhibitory effect of xylitol on the activity of 
α-glucosidase activity in the hydrolysis of disaccharide or degradation products resulting from 
starch hydrolysis. This was determined according to methods modified from Wu et al., 2012. 
The principle of this assay was based on the fact that α-glucosidase can hydrolyze 
paranitrophenyl-α-D-glucopyranoside (PNPG) to release paranitrophenol that absorbes light at 
405 nm. 
                         PNPG    
 α-glucosidase
      α-D-glucose   +     paranitrophenol           
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3.2.2.1 Preparation of Reagents 
Preparation of 500 mL of assay buffer (0.1 M sodium phosphate buffer, pH 6.9): This was 
prepared as follows: 
A 500 mL of 0.1 M mono-basic sodium phosphate solution was prepared by dissolving a 5.999 g 
of mono-basic sodium phosphate (M.W., 119.98 g/mol) in 500 mL of distilled water (dH2O) 
 
A 500mL of 0.1 M dibasic sodium phosphate solution was prepared by dissolving a 7.078 g of 
dibasic sodium phosphate (M.W., 141.56 g/mol) in 500 mL of dH2O 
 
0.1 M mono-basic sodium phosphate solution was steadily added to 0.1 M dibasic sodium 
phosphate solution, while stirring until a pH of 6.9 was attained 
 
This was stored in the refrigerator until further use. 
 
Preparation of 500 mL of 5 mM Paranitrophenyl glucopyranoside (PNPG) substrate 
solution: This was prepared by dissolving 0.07531 g (M.W., 301.25 g/mol) in 50 mL of assay 
buffer. 
Preparation of 25 mL of 1 U/mL α-glucosidase enzyme solution: This was prepared by 
making up 0.667 mL of 37.5 U/mL S. cerevisiae α-glucosidase enzyme solution to 25 mL with 
assay buffer. 
Preparation of 100 mL of 0.2 M sodium bicarbonate (Na2CO3): This was prepared by 
dissolving 2.1198 g of Na2CO3 (M.W., 105.99 g/mol) in 100 mL of dH2O. 
Preparation of 50 mL each of 2.5%, 5%, 10%, 20%, 30% and 40% w/v xylitol solutions: 
This was prepared by dissolving 1.25 g, 2.5 g, 5 g, 10 g, 15 g and 20 g of xylitol in 50 mL of 
assay buffer respectively. 
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3.2.2.2 Assay Procedure 
Assay procedure was performed in triplicates as described in the following flow chart: 
A 0.5 mL of sample (2.5% - 40% w/v xylitol solutions) or 0.5 mL of assay buffer (for control) 
and 1 mL of 1 U/mL α-glucosidase solution or 1.5 mL of assay buffer for blank was added into a 
test tube, mixed properly and incubated for 10 min at 25 OC after mixing well 
 
A 0.5 mL of substrate (5 mM PNPG solution) was added to mixture and incubated for 5 min at 
25 OC 
 
A 2 mL of 0.2 M Na2CO3 solution was then added to stop the reaction for 5 min incubation at 25 
OCand absorbance was read at 405 nm after incubation. 
 
3.2.2.3 Calculation of Percentage Inhibition of α-Glucosidase Enzyme Activity 
Percentage inhibition was calculated using the following formula: 
% Inhibition = [(AbsC – AbsS)/AbsC]  x 100 
Where, “AbsC” and “AbsS” mean absorbance of control and samples at 405 nm respectively. 
 
3.3 Ex-vivo Study 
3.3.1 Animal Procedures 
Five adult male Spagrue-Dawley rats with mean body weight 201.12 ± 12.48 were procured 
from the Biomedical Resource Center located at the Westville Campus of the University of 
KwaZulu-Natal, Durban, South Africa. The animals were fasted over-night (12 hours) and 
euthanized by halothane anesthesia. The abdominal wall was dissected and the whole 
gastrointestinal tract (GIT) and parts of the psoas muscle were collected and immediately used 
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for assays. All animal procedures were carried out according to the rules and regulations of the 
Animal Ethics Research Committee of University ofKwaZulu-Natal, South Africa (Ethical 
approval number: 097/13/Animal). 
 
3.3.2 Measurement of Glucose Absorption in Isolated Rat Jejunum 
The effect of xylitol on glucose absorption by isolated rat intestine was determined using 
methods modified from Hassan et al., 2010. 
 
3.3.2.1 Preparation of Reagents 
Preparation of 1 L Kreb’s buffer: Kreb’s buffer is compose of 118 mM sodium chloride 
(NaCl), 5 mM potassium chloride (KCl), 1.328 mM calcium chloride dehydrate (CaCl2.2H2O), 
1.2 mM potassium mono-basic phosphate (KH2PO4), 1.2mM magnesium sulphate (MgSO4) and 
25 mM sodium hydrogen bi-carbonate (NaHCO3). A 1 L of Kreb’s buffer was prepared by 
dissolving 6.896 g of NaCl (M.W., 58.44 g/mol), 0.373 g of KCl (M.W., 74.56 g/mol), 0.188 g 
of CaCl2.2H2O (M.W., 147.02 g/mol), 0.163 g of KH2PO4 (M.W., 136.09 g/mol), 0.144 g of 
MgSO4 (M.W., 120.37 g/mol) and 2.10 g of NaHCO3 (M.W., 84.01 g/mol) in 1 L of autoclaved 
dH2O. 
Preparation of 500 mL of 11.1 mM glucose Kreb’s solution (GKS): This was prepared by 
dissolving 0.9999 g of D-glucose (M.W., 180.16 g/mol) in 500 mL of Kreb’s buffer. 
Preparation of 50mL of 3 mM acarbose solution: This was prepared by dissolving 0.09648 g 
of acarbose (M.W., 645.6 g/mol) in 50 mL of GKS. 
Preparation of 100 mL of 10%, 20% and 40% w/v xylitol solutions: This was prepared by 





3.3.2.2 Assay Procedure 
The assay procedure was performed in five replicates as described in the following flow chart: 
Five 5 cm length of jejunum was cut from isolated GIT of rats and each jejunum was rinsed by 
injecting 2 mL of Kreb’s buffer through the jejuna lumen using a sterile syringe. 
 
Rinsed jejuna were first inverted to expose their inner wall and villi, and then incubated in 
carbon (iv) oxide (CO2) incubation tubes containing 8 mL each of GKS solution (control), 10%, 
20% and 40% w/v xylitol solutions and 3 mM acarbose solution (positive control) for 2 hours in 
a Steri-Cult CO2 incubator (Labotec, South Africa) at 5% CO2, 95% Oxygen and 37 OC 
condition. 
 
A 1 mL aliquot was collected from each incubation solution before and after incubation and the 
glucose concentrations were measured in milligram per deciliter (mg/dL) with Thermo Scientific 
glucose kit in a Labmax Plenno Chemistry Analyzer (Labtest Inc., Costa Brava, Brazil). 
 
3.3.2.3 Calculation of Intestinal Glucose Absorption 
This was calculated as the amount of glucose in milligram absorbed per centimeter of rat 
jejunum using the following formula: 
Intestinal glucose absorption =     (GC1  -  GC2)/ 5cm of jejunum 







3.3.3 Measurement of Glucose Uptake in Isolated Rat Psoas Muscles 
The effect of xylitol on glucose uptake in isolated rat psoas muscles was determined according to 
methods modified from Abdel-Sattar et al., 2012. 
3.3.3.1 Preparation of Reagents 
Preparation of 50 mL 1 mg/mL metformin solution: This was prepared by dissolving 50mg of 
metformin in 50 mL of glucose Kreb’s solution (GKS). 
 
3.3.3.2 Assay Procedure 
The assay was carried out in triplicates as described in the following flow chart: 
Three pieces of 0.5 g was cut from the psoas muscles collected from each rat and incubated in 
CO2 incubation tubes containing 8 mL each of GKS (control), 10%, 20% and 40% w/v xylitol 
solutions and 1 mg/mL metformin solution (positive control) for 1 hour in a Steri-Cult CO2 
incubator (Labotec, South Africa) at 5% CO2, 95% Oxygen and 37 OC condition. Each 0.5 g of 
muscle tissue was incubated with and without 100 mU/ mL of insulin. 
 
A 1 mL aliquot was collected from each incubation solution before and after incubation and the 
glucose concentrations were measured in milligram per deciliter (mg/dL) with Thermo Scientific 
glucose kit in a Labmax Plenno chemistry analyzer (Labtest Inc., Costa Brava, Brazil). 
 
3.3.2.3 Calculation of Muscle Tissue Glucose Uptake 
This was calculated as the amount of glucose in milligram taken up per gram of rat psoas muscle 
tissue using the following formula: 
Muscle glucose uptake =          (GC1  -  GC2)/ 0.5 g of muscle tissue 
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Where, “GC1” and “GC2” are glucose concentrations (mg/dL) before and after incubation, 
respectively. 
 
3.4 In vivo Study 
3.4.1 Animals 
Thirty-one seven-week-old male Sprague-Dawley rats with mean body weight 222.23 ±13.50 g, 
procured from the Biomedical Resource Center located at the Westville Campus of the 
University of KwaZulu-Natal, Durban, South Africa were randomly grouped into five groups, 
namely normal control (NC), normal xylitol (NXYL), diabetic control (DBC), diabetic xylitol 
(DXYL) and diabetic acarbose (DBA), which had five animals in each normal animal group and 
seven animals in each diabetic animal group. The animals were housed in a two-in-one medium-
sized poly carbonated cage. The cages were kept in a temperature- and humidity-controlled room 
with a 12-hour light-dark cycle. All animals were fed with a commercial rat pellet diet and were 
maintained according to the rules and regulations of the Experimental Animal Ethics Committee 
of the University of KwaZulu-Natal, South Africa during the entire experimental period (Ethical 
approval number: 097/13/Animal). 
 
3.4.2 Induction of Diabetes 
During the first 2 weeks of the experiment, the animals in the DBC, DXYL and DBA groups 
were supplied with a 10% fructose solution to induce insulin resistance while the animals in the 
NC and NXYL groups were supplied with normal drinking water. Thereafter, animals in the 
DBC, DXYL and DBA groups were intraperitoneally injected with low dose of streptozotocin 
(40 mg/kg body weight) dissolved in a citrate buffer (pH 4.5) to induce partial pancreatic β -cell 
dysfunction, while animals in the NC and NXYL groups were injected with a similar volume of 
citrate buffer only. One week after the streptozotocin injection, the nonfasting blood glucose 
(NFBG) levels of all animals were measured in the blood collected from the tail vein by using a 
portable Glucoplus glucometer (Glucoplus Inc., Saint- Laurent, Que., Canada), and animals with 
a NFBG level  ≥ 300 mg/dl were considered to be diabetic. Animals with a NFBG level < 300 
mg/dl were excluded from the study.  
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3.4.3 Feeding and Sampling 
One week after the STZ injection or induction of diabetes, all animals were fasted overnight (16 
hours) with free access to drinking water only. After fasting, the animals in the NXYL, DXYL 
and DBA groups were administered with a single oral dose of xylitol (1 g per kg body weight for 
NXYL and DXYL groups) and acarbose (200 mg per kg body weight for DBA group) with 
glucose (2 g per kg body weight), containing 0.05% (w/v) of phenol red (recovery marker) as 
stated for each group in the following  animal experiment flow diagram, while only glucose with 
phenol red were administered to NC and DBC group. Animals were then sacrificed by halothane 
anesthesia exactly 1hour after the dose administration, without any access to drinking water. The 
whole gastro-intestinal tract was removed as quickly as possible and frozen immediately in 
liquid nitrogen to prevent the movement of gastro-intestinal contents, and immediately preserved 
at -30OCfor subsequent analysis. 
 
3.5.3  Sample Preparation 
Samples collected were prepared as follows: 
The whole GIT was thawed and divided into eight segments: Stomach (St) 1st, 2nd, 3rd, and 4th 
quarter of the small intestine (S1, S2, S3, and S4); Cecum (Ce); Proximal and distal half of the 
Colon (L1 and L2). 
 
The weight of each segment was measured with and without content and the content of each 
segment was collected by using a syringe to inject 10 mL of cold normal saline (0.9% Sodium 
Chloride solution) through segments. 
 
The weight of content in each segment was determined by subtracting the weight of segment 




Both GIT tissue segments and contents were homogenized using an Ultra Turrax Tube Drive  
Work Station homogenizer (IKA Laboratory equipment, Staufen, Germany) in 10 mL of cold 
normal saline and centrifuged twice using a Hettich Mikro 200 microcentrifuge (Hettich Lab 
Technology, Tuttlingen, Germany) at 15,000 rpm for 30 min. 
 
Supernatant was collected in another 2mL micro tube and stored at -20OC for further analysis. 
The following analysis or assays were performed on both tissue and content homogenates of GIT 
segments: 
 Determination of glucose concentrations 
 Determination of phenol red concentration. 
 
3.6.3 Determination of Glucose Concentration 
Glucose concentrations in GIT tissue and content of segments were measured in milligram per 
deciliter (mg/dL) with a Thermo Scientific glucose kit in a Labmax Plenno Chemistry Analyzer 
(Labtest Inc., Costa Brava, Brazil), using the principle of the glucose oxidase method. The 
hydrogen peroxide produced from the oxidation of glucose by glucose oxidase enzyme is reacted 
with 4-hdroxybenzoic acid and 4-aminoantipyrine in the presence of peroxidase enzyme to form 
a red quinoneimine dye, in which its absorbance between 460 nm and 560 nm is proportional to 
the glucose concentration of sample homogenates (Trinder, 1969). 
Reaction 1:Glucose  +  O2  +  H2O2
Glucose Oxidase     Gluconic Acid  +   H2O2 
Reaction 2:H2O2  +  4-HBA  +  4-AAP      
Peroxidase           Quinoneimine dye (red)  +  H2O2 
Where, 






















FIGURE 3.1: Flow diagram outlining the experimental design of animal experiment for in vivo 
study. 
 
Week 0                                                                                                                                                                             










Week 1-2                                          
Normal drinking waterad libitum 
Week 1-2                                                                                  
10% Fructose solution provided ad libitum 
 
Week 3                                                                                                
equal volume of Intraperitoneal 
citrate buffer injection    without 
Streptozotocin 
 
Week 3                                                                                 
Intraperitoneal streptozotocin (in citrate buffer) 
injection (40 mg/kg B.W.) 
 
Week 4Measure NFBG: Between 300-600 mg/dL 
is considered diabetic and used for study 
Week 4Measure NFBG 
Week 5 Administration of a single bolus dose as described below for each group containing 










(2 g/Kg B.W.) 








(DBA)                   
 
NXYL: Glucose 
(2 g/Kg B.W.) 
and Xylitol (1 
g/Kg B.W.) 
DBA: Glucose (2 




All animals was euthanized using halothane 1 hour after bolus dose administration and the 
whole gastrointestinal tract collected, frozen and preserved appropriately for further analysis. 
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Amounts of glucose in grams that was given to animals or recovered from segments were 
calculated using the following formula: 
Amount of glucose given (g) = Concentration bolus dose (g/mL)  x   Volume of bolus dose (mL). 
Amount of glucose recovered (g) =     [(cT or cC)/ 100,000]   x    Homogenization volume (mL) 
Where, 
“cT”  =  Concentration of glucose (mg/dL) recovered from GIT tissue of segments 
“cC” =   Concentration of glucose (mg/dL) recovered from GIT content of segments 
100000 mg/dL  =  1 g/mL. 
 
3.6.4 Determination of Phenol Red Concentration 
Phenol red concentration was determined according to methods described by French et al., 1968 
with slight modification. The principle of the assay is based on the fact that phenol red in a 
solution will change from an orange red colour to pink or violet colour under alkaline condition, 
in which the absorbance at 560 nm is proportional to the concentration of phenol red in the 
sample solution. 
 
3.6.4.1 Preparation of Reagents 
Preparation of 25 mL 0.1 M Sodium Hydroxide Solution: This was prepared by dissolving 
0.1 g of sodium hydroxide (M.W., 40 g/mol) in 25 mL of distilled water. 
Preparation of 1 liter of 0.1 M Sodium Phosphate buffer (pH, 10.5): This was prepared 
according to the following chart: 
A 1 L of 0.1 M dibasic sodium phosphate solution was prepared by dissolving 14.16 g of dibasic 




A 0.1 M sodium hydroxide was steadily added to 0.1 M dibasic sodium phosphate solution, 
while stirring until a pH of 10.5 was attained. 
 
This was stored in the refrigerator until further use. 
Preparation of Phenol Red Standard Solutions: The phenol red standard solutions with 
increasing concentrations of 0.0038%, 0.0018%, 0.001%, 0.0005% and 0.00025% w/v were 
prepared according to the following chart: 
A 5 mL of 0.05% w/v phenol red solution was first prepared by dissolving 0.0025 g of phenol 
red in distilled water. 
 
This solution was then diluted 10 times to a final concentration of 0.005% w/v by making up 
0.5mL of the solution (0.05% w/v) to 5mL with distilled water. 
 
Then, 500µL of phenol red standard concentrations was prepared by making up, 380 µL, 180 µL, 
100 µL, 50 µL and 25 µL of 0.005% w/v solution to 500 µL with distilled water to give phenol 
red standard concentrations of 0.0038%, 0.0018%, 0.001%, 0.0005% and 0.00025% w/v 
respectively. 
 
3.6.4.2 Assay Procedure 
Assay procedure is described in the following flow-chart: 
A 30 µL of sample homogenates or phenol red standards or 0.1 M sodium hydroxide solution 




Then a 210 µL of 0.1 M dibasic sodium phosphate solution (pH, 10.5) was added and mixed 
gently. 
 
Absorbance was read at 560 nm for phenol red concentration and at 420 nm to correct for bile 
pigment using a Spectrostar Nano spectrophotometer (Bmg Labtech, Offenburg, Germany). 
 
3.6.4.3 Calculation of Phenol Red Concentrations of Samples 
Phenol Red concentrations of samples were calculated as according to the following flow chart: 
The absorbance at 560 nm of the phenol red standards was first plotted against their 
corresponding concentrations using Microsoft Excel, 2007 program to obtain a standard curve. 
 
From the phenol red standard curve, the phenol concentrations of each sample was extrapolated 
from their respective absorbance at 560 nm. 
Amounts of phenol red (PR) in grams that was given to animals or recovered from segments 
were calculated using the following formula: 
Amount of PR given (g) = [Concentration bolus dose (% w/v)/ 100]  xVolume of bolus dose 
(mL).      
Amount of PR recovered (g)  =[(cT or cC)/100]     x     Homogenization volume (mL) 
Where, 
“cT”  =  Concentration of PR (% w/v) recovered from GIT tissue of segments. 
“cC” =   Concentration of PR (% w/v) recovered from GIT content of segments. 





                                                                                                  Scale: Y-axis: 0.1 units rep 1cm                 
                                                                                                      X-axis:  0.0005  units rep 1cm 
FIG 3.2: Phenol red standard curve: a graph of absorbance of phenol red standard solutions 
versus standard concentrations. 
Percentage recovery of phenol red in GIT tissue or contents of segments was calculated using the 
following formular: 
Percentage recovery in given segment (%) = [(aT or aC)/ Amount of PR given (g)]    x  100 
Where, 
“aT”  =  Amount of PR (g) recovered from GIT tissue of that particular segment. 
“aC” =   Amount of PR (g) recovered from GIT content of that particular segment. 
y = 176.67x - 0.0081 
























Concentration (% w/v) 
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Total percentage recovery of phenol red for each animal was equivalent to the percentage phenol 
red recovered from the entire GIT, which was given by the sum total of the percentage recovery 
of both tissue and content of all segments. 
 
3.6.5 Calculation of In Vivo Parameters 
Amounts of phenol red and glucose recovered from GIT segments were used as indices to 
calculate the following parameter according to methods described by Islam and Sakaguchi 
(2006), which were expressed in percentages: 
 Gastric emptying of the stomach 
 Glucose absorption index (GAI) in the GIT 
 Digesta transit along the GIT 
 
3.6.5.1 Calculation of Stomach Gastric Emptying 
This parameter denotes the extent or degree to which the stomach empties its content that was 
ingested. It was calculated using the following formula: 
Gastric emptying (%) =  [(A – B)/ A]  x  100 
Where, 
“A” = Total amount of PR (g) recovered from the whole GIT 
“B” = Total amount of PR (g) recovered from the stomach 
 
3.6.5.2 Calculation of Glucose Absorption Index (GAI) 
This denotes the extent to which glucose is absorbed at each segment of the GIT. It is the 
percentage of glucose passing through a given segment that was absorbed. It was calculated 
using the following formula: 
63 
 
GAI (%) in a given segment of the GIT  =(1  -  [(a/b)/(c/d)])    x   100 
Where, 
“a”  =  Amount of glucose (g) recovered from that segment 
“b”  =  Amount of PR (g) recovered from the same segment 
“ c”  =  Amount of glucose (g) given to corresponding animal 
“d”  =  Amount of PR (g) given to corresponding animal 
 
3.6.5.3 Calculation of Digesta Transit 
This denotes the degree or extent to which GIT content passes from one segment to the next. It is 
the percentage rate at which GIT content transits along the intestine. The digesta transit at a 
given segment of the GIT is expressed a percentage ratio of the amount of GIT content leaving 
that particular segment to the amount reaching the same segment, and it was calculated using the 
following formula: 
Digesta transit in a given segment (%)  =  (a / b) x 100 
Where, 
“a”  =   Amount of phenol red (g) recovered from that particular segment of the GIT to the distal 
colon excluding the amount of phenol red (g) recovered from that particular segment. 



























4.1 Effects of Xylitol on the Activities of Alpha Amylase and Alpha Glucosidase 
The data showing the effects of increasing concentrations of xylitol on in vitro alpha amylase 
enzyme activity are represented in figure 4.1a. Result showed that there was an in vitro inhibition 
of alpha amylase enzyme activity in the presence of xylitol compared to the absence of xylitol. 
However, this inhibition was concentration-dependent. Increasing concentrations of xylitol from 
2.5% to 40% caused corresponding increase of enzyme activity inhibition, with IC50 value of 
21.69% w/v of xylitol (Figure 4.1a). Xylitol concentrations at 40% showed the highest enzyme 
inhibition, which was relatively higher than concentrations at 20% and 30%, but significantly 
higher (p< 0.05) than concentrations at 2.5%, 5% and 10%, when there was no significant 
difference between concentrations at 5% and 10% (Figure 4.1a). Lower inhibition was observed 




Figure 4.1: Graph showing the effect of xylitol on activities of alpha amylase (a)and alpha 
glucosidase (b)in vitro. Data are presented as mean ± SD of triplicates of analysis. Different letters presented 
above the bars for a given enzyme are significantly different from each other (p < 0.05. Tukey’s HSD post-hoc test, 
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Figure 4.1b represents data showing the in vitro effects of increasing concentrations of xylitol on 
alpha glucosidase enzyme activity. Compared to the control, which was without xylitol, all 
concentration of xylitol showed enzyme activity inhibition. This was also in a concentration-
dependent manner, because increasing concentrations of xylitol caused a concomitant increase in 
enzyme activity inhibition with IC50 value of 17.58% w/v xylitol (Figure 4.1b). Enzyme activity 
inhibition at all concentrations where significantly different from each other (p< 0.05), except for 
between concentrations at 30% and 40%, which both showed the significantly higher (p< 0.05) 
enzyme activity inhibition compared to all other concentrations (Figure 4.1b). 
 
4.2 Effects of Xlitol on Glucose Absorption in Isolated Rat Jejunum 
The data showing the effects of xylitol on in vitro glucose absorption in isolated rat jejunum are 
presented in Figure 4.2. The result showed that the amount of glucose absorbed by isolated rat 
jejunum in the presence of xylitol was concentration-dependent. Amount of glucose absorbed 
was lowest at 40% xylitol (1.75 ± 0.46 mg/cm jejunum), which was significantly different (p< 
0.05) from the control (3.27 ± 0.46 and mg/cm jejunum) and concentrations at 10% xylitol (3.27 
± 0.67 mg/cm jejunum), but not significantly different from the amount of glucose absorbed at 






Figure 4.2: Graph showing the effects of xlitol onglucose absorption in isolated rat jejunumin 
vitro. Data are presented as mean ± SD of five replicates of analysis. Different letters presented above the bars for 
a given xylitol concentration are significantly different from each other (p < 0.05. Tukey’s HSD post-hoc test, IBM, 
SPSS, version 21). 
 
4.3 Effects of Xlitol on Glucose Uptake by Isolated Rat Psoas Muscle 
The effect of xylitol on in vitro glucose uptake in isolated rat psoas muscle is presented in figure 
4.3. Data showed that the amount of glucose uptake by psoas muscle in the presence of xylitol 
was also concentration dependent. This was highest at 40% xylitol with and without insulin 
(54.00 ± 5.29 and 54.70 ± 16.29 mg/g tissue weight respectively), which was significantly 
different (p< 0.05) from the control but not significantly different from the amount of glucose 
uptake at 10% and 20% xylitol, and 1 mg/mL metformin (Figure 4.3). Although not significantly 
different, the amount of glucose uptake by isolated muscle tissues was higher at 10% and 20% 
xylitol concentrations compared to the control, but lower compared to 1 mg/mL metformin. 
Furthermore, there was no significant difference in the amount of glucose uptake between the 











































Figure 4.3: Graph showing the effects of xlitol onglucose uptake in isolated rat psoas muscle in 
vitro. Data are presented as mean ± SD of triplicates of analysis. Different letters (“x” and “y”or “a” and “b”) 
presented above the bars for a given xylito concentration (with or without insulin respectively) are significantly 
different from each other (p < 0.05. Tukey’s HSD post-hoc test, IBM, SPSS, version 21). 
 
4.4  Effects of Xylitol on In Vivo Intestinal Glucose Absorption and Related Parameters 
The data showing the effects of xylitol on in vivo intestinal glucose absorption and other related 
parameters like nutrient gastric emptying, digesta transit and fluid volume, which can directly or 
indirectly affect intestinal absorption of glucose, are presented in Figure 4.4 to 4.9. Phenol red 
was used as a recovery marker to estimate the above mentioned parameters in both normal and 
diabetic rats. The mean of the total amount of phenol red recovered from the entire 
gastrointestinal tract(GIT) of all experimental animals was 84.96 ± 10.34%, which was 
















































                                               Small intestine                                                      Large intestine             
Figure 4.4:Data showing the distribution of phenol red (marker) in the different segments of the 
GIT at 1 hour after the dose ingestion. Data are presented as mean ± SD of five to six animals. Different 
letters presented above the bars for a given segment are significantly different from each other group of animals (p 
< 0.05. Tukey’s HSD post-hoc test, IBM, SPSS, version 21). 
 
The general distribution of phenol red across the different GIT segments was relatively higher in 
the stomach, distal half of the small intestine and cecum, and lower in the proximal end of the 
small intestine and colon (Figure 4.4). In the stomach, the phenol red recovered was significantly 
higher (p< 0.05) in the NXYL and DXYL groups compared to the DBC and DBA groups, but 
only relatively higher compared to the NC group, when there was no significant difference 
between the NC, DBC and DBA groups. The phenol red distribution of the DBC group was 
significantly higher (p< 0.05) compared to the NXYL group in the 1st quarter of the small 
intestine, but compared to the NXYL and DXYL in the 2nd and 3rd quarters, when no significant 
difference was observed when comparing between other groups of the 1st quarter. In the 4th 
quarter of the small intestine and distal half of the colon, there was no significant difference in 
phenol red distribution between the NC and NXYL groups as well as between the DBC and 
DXYL groups, where as in the cecum, the phenol red distribution of the NXYL and DXYL 













































































Figure 4.5: Data showing the gastric emptyingat 1 hour after the dose ingestion. Data are presented 
as mean ± SD of five to six animals.Different letters presented above the bars for a given group are significantly 
different from each other group of animals (p < 0.05. Tukey’s HSD post-hoc test, IBM, SPSS, version 21). 
 
The data showing the gastric emptying of the stomach for all groups are presented in Figure 4.5. 
The gastric emptying of the NXYL and DXYL groups was significantly lower (p<0.05) 
compared to the DBC and DBA groups, when no significant difference was observed between 
the NC and all other groups. However, the gastric emptying of the NC group was relatively 
higher compared to the NXYL and DXYL groups, but relatively lower compared to the DBC and 

































                                       Small intestine                                                      Large intestine 
Figure 4.6: Data showing the glucose absorption index (GAI) in the different segments of the 
GIT at 1 hour after the dose ingestion.Data are presented as mean ± SD of five to six animals. Different 
letters presented above the bars for a given segment are significantly different from each other group of animals (p 
< 0.05. Tukey’s HSD post-hoc test, IBM, SPSS, version 21). 
 
The data showing the intestinal glucose absorption index (GAI) are presented in Figure 4.6. In 
the 1st quarter of the small intestine, the GAI of the NXYL and DXYL groups was significantly 
lower (p< 0.05) compared to the NC, DBC and DBA groups, when there was no significant 
difference between NC, DBC and DBA groups, as well as between the NXYL and DXYL 
groups. In the normal rats, the GAI of the NXYL group was significantly lower (p< 0.05) in the 
2nd and 3rd quarters of the small intestine, and distal half of the colon, but insignificantly lower in 
the last quarter of the small intestine compared to the NC group. In the diabetic animals, the GAI 
of the DXYL group in all these segments was relatively lower compared to the DBC and DBA 
groups. In the 1st quarter of the small intestine, the GAI was significantly lower (p< 0.05) in the 
DXYL group compared to the NC, DBC and DBA groups. However, in the 3rd and last quarters 
of the small intestine, and distal half of the colon, the GAI of the DXYL group was significantly 
lower (p< 0.05) compared to the NC group, when no significant difference was observed 
between similar groups in the 2nd quarter of the small intestine (Figure 4.6). No significant 
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difference was observed in the cecum and proximal half of the colon when comparing between 
all groups. 
 
Table 4.1:Data showing the percentage of digesta transit in the different segments of the GIT 
during 1 hour of experimental period.  
GROUP S1 S2 S3 S4 Ce L1 
  Digesta Transit (%)   
NC 93.38 ± 1.77 83.23 ± 3.32 71.25 ± 5.28a 65.56 ±5.82 51.71 ± 3.73a 48.53 ± 8.09a 
NXYL 94.53 ± 2.54 86.94 ± 2.20 81.06 ± 2.03b 69.20 ± 4.72 38.98 ± 8.13b 49.40 ± 6.20a 
DBC 91.11 ± 1.63 82.65 ± 5.49 70.98 ± 4.83a 71.68±14.15 48.61 ±6.17ab 58.61 ± 8.10ab 
DXYL 91.54 ± 0.17 84.24 ± 4.14 81.16 ± 4.42b 75.02 ± 4.12 41.31 ± 3.75b 54.40 ± 4.55ab 
DBA 91.77 ± 3.20 84.33 ± 5.68 64.45 ± 6.29a 69.55 ± 9.89 55.5 ± 5.53a 64.8 ± 13.91b 
Data are presented as mean ± SD of five to six animals. Different letters presented in each column for a given 
segment are significantly different from each other group of animals (p < 0.05. Tukey’s HSD post-hoc test, IBM, 
SPSS, version 21). 
 
The data for percentage of digesta transit in the different segments of the GIT of all groups are 
presented in Table 4.1. The digesta transit for all groups was generally decreased from the small 
intestine to the cecum, and increased from the cecum to the colon. Although the digesta transit in 
the 1st and 2nd quarters of the small intestine did not differ significantly when comparing between 
the groups, the digesta transit of the xylitol fed groups (NXYL and DXYL) was relatively higher 
than their respective controls groups (NC and DBC). Nevertheless, in the 3rd quarter of the small 
intestine, the digesta transit of the NXYL and DXYL groups was significantly higher (p< 0.05) 
compared to the NC, DBC and DBA groups, when there was no significant difference between 
the NC, DBC and DBA groups, as well as between the NXYL and DXYL groups (Table 4.1). 
There was no significant difference between all groups in the last quarter of the small intestine. 
However, in the cecum, the digesta transit of the NXYL and DXYL groups was significantly 
lower (p< 0.05) compared to the NC and DBA groups but relatively lower compared to the DBC 
group, when no significant different was observed between the NC, DBC and DBA groups, as 
Small intestine Large intestine 
73 
 
well as between the NXYL and DXYL groups. Digeta transit was not significantly affected at all 




                                                                          (b) 
Figure 4.7: Data showing the relationship between the intestinal fluid volume and glucose 
absorption index in the different segments of the GIT of NC and NXYL groups (a) and DBC and 
DXYL groups (b). Data are presented as mean ± SD of five to six animals.Different letters (“a” and “b”or “x” 
and “y”) presented near the lines for a given segment of each parameter (fluid volume or GAI respectively) are 
significantly different from each other (p < 0.05. Tukey’s HSD post-hoc test, IBM, SPSS, version 21). 
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The data showing the relationship between the fluid volume and glucose absorption index (GAI) 
are presented in Figure 4.7. The fluid volume of all groups, which was equivalent to the mass of 
content in each segment of the GIT (i.e., 1 g of content was considered equivalent to 1 mL of 
fluid volume) was highest in the cecum compared to other segments of the GIT (Figure 4.7a and 
b). In the 1st, 2nd and 3rd quarters of the small intestine, the fluid volume of the xylitol treated 
groups (NXYL and DXYL) was significantly higher (p< 0.05) compared to their corresponding 
control groups (NC and DBC) (Figure 4.7a and b). In the last quarter of the small intestine, the 
fluid volume of the NXYL group was significantly higher (p< 0.05) than the NC (Figure 4.7a), 
when there was no significant difference between the DBC and DXYL groups (Figure 4.7b). In 
the proximal and distal halves of the colon, the fluid volume of the NXYL group was 
significantly higher and lower (p< 0.05) respectively compared to the NC group (Figure 4.7a), 
when no significant difference was observed between the DBC and DXYL groups of similar 
segments (Figure 4.7b). In the cecum, no significant difference was observed between the NC 
and NXYL groups and between the DBC and DXYL groups (Figure 4.7a and b). The overall 
relation between the fluid volume and GAI in the GIT was an inverse relation, i.e. the more the 
fluid volume, the lesser the GAI at the different segments of the GIT (Figure 4.7a and b). 
The correlation graphs between fluid volume and GAI in the different segments ofthe GIT are 
presented in Figure 4.8, which showed that both parameters across all segments of the GIT in the 
non-diabetic groups were inversely related or proportional, but no significant correlation was 










                         (a): NC and NXYL(b): DBC and DXYL 
 
(c): DBC and DBA 
 
Figure 4.8: Correlation plot between the glucose absorption index (Y axis) and intestinal fluid 
volume (X axis) in the different segments of theGIT of NC-and NXYL-(a); DBC-    and DXYL-  
(b); DBC-and DBA-   (c).Data are presented as the mean ± SD of five to six animals. Significant correlation 
denotes p < 0.05 (Analysis ToolPak, Microsoft excel, Microsoft Corporation). 
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In recent years, xylitol is being widely used as a sugar substitute because of its severalbeneficial 
effects on health compared to other commonly used sweeteners. The lower caloric value (2.4 
kcal vs 4.0 kcal/g), insulinemic response, lower glycemic index (13) and similar sweetness 
compared to sucrosehave made it more popular to poeple. In a recent study, it has been reported 
that xylitol exhibits significant anti-diabetic and hypoglycemic effects in a type 2 diabetes model 
of rats(Islam and Indarjit, 2012). The present study was conducted in order to investigate and 
understand the possible mechanisms behind the anti-diabetic effects of xylitol using several in 
vitro and in vivo models. 
The action of carbohydrate hydrolyzing enzymes on carbohydrate-containing diet has a 
significant effect on postprandial blood glucose level, and delaying the digestion of carbohydrate 
like starch and sucrose will translate into lower postprandial blood glucose (Dhital et al., 2013; 
Reuser and Wisselaaar, 1994). Alpha glucosidase and alpha amylase inhibitors have gained 
much popularity as a class of hypoglycemic agents, which reduces postprandial blood glucose 
via this mechanism by inhibiting the action of alpha glucosidase and alpha amylase enzymes 
(Bischoff, 1994 and 1995; Patel et al., 2012). The result from our in vitro study showed a 
significant inhibition of alpha amylase and alpha glucosidase enzyme activities by xylitol (Figure 
4.1a and b), which is an indication that xylitol may possess significant inhibitory effect on 
carbohydrate breakdown. This can result in reducing the levels of postprandial blood glucose, 
which may partly be involved in the mechanism behind the hypoglycemic effects of xylitol. 
The major dietary source of glucose for human comes from starchy foods and other similar 
carbohydrates, and the degree of absorption of digested starch (glucose) is an important factor 
that can play a major role in the development of diabetes, obesity and related metabolic disorders 
(Dhital et al., 2013). Glucose is rapidly absorbed in the intestine by a mechanism of facilitated 
diffusion, and results from previous in vitro studies have suggested the elevated capacity of 
glucose absorption across all segments of the small intestine (Fearson and Bird, 1968), with the 
mid-small intestine (part of the duodenum and jejunum) having the highest absorption capacity 
(Lavin, 1976). In the present study, a 2 hour incubation of isolated rat jejunum in a glucose 
solution with the villi exposed, showed glucose absorption as high as 3.27 ± 0.46 mg/cm of 
jejunum in control or when no xylitol was used. However, in the presence of 40% xylitol, there 
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was a significant reduction in the glucose absorption capacity (1.75 ± 0.46 mg/cm of jejunum), 
which is an indication of the possible inhibitory potentials of xylitol on intestinal glucose 
absorption, which might be partly involved in the mechanism behind the hypoglycemic effects of 
xylitol. 
Among other functions, insulin produced in the body helps to stimulate the uptake of circulating 
glucose by actively respiratory cells for energy production, thus lowering and maintaining blood 
glucose homeostasis (Mathews et al., 2000). In previous study, Muller-Hess et al., (1975) 
reported that blood glucose and serum insulin was significantly increased by oral administration 
of 30 or 50 g of xylitol in normal subjects, while in some other studies, it has been reported that 3 
to 5 weeks oral administration of 10% xylitol increased serum insulin in both normal and 
diabetic rats (Islam, 2011; Islam and Indarjit, 2012). Since the reduction in circulating glucose 
uptake can cause reduced clearance of blood glucose, which could be a pathogenic route to the 
observed hyperglycemia in diabetic rats (Chaiken et al., 1993), it is therefore rationale and 
reasonable to investigate the effects of xylitol on glucose uptake in isolated rat psoas muscle 
using an in vitro model. The results from our study showed that xylitol significantly increased 
glucose uptake in isolated rat psoas muscle compared to the control (without xylitol). This 
suggests that xylitol may improve the uptake of circulating glucose, which might partly 
contribute to the anti-diabetic as well as hypoglycemic potential of xylitol. Insulin did not 
significantly contribute to the glucose uptake of xylitol, although it appreciably increased 
glucose uptake in the control and 10% xylitol. However, direct effect of xylitol on muscle 
glucose uptake without insulin suggests thatxylitol may have insulin-like effects on skeletal 
muscle in the stimulation of circulating glucose uptake (Abdel-Sattar et al., 2012; Gupta et al., 
2005). 
The concentration range of xylitol used in the ex vivostudies were chosen based on the 
concentration of xylitol used in previous study (Islam, 2011; Islam and Indarjit, 2012). Although 
these concentrations were high relative to the concentration of glucose used, the results 
suggested concentration dependent effects of xylitol, comparing the effects of different xylitol 
concentrations. 
In order to further investigate the inhibitory potential of xylitol on intestinal glucose absorption 
in in vitro environment, an in vivo study was conducted and several intestinal nutrient 
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absorption-related parameters that can directly or indirectly affect the glucose absorption were 
estimated. Phenol red was used as a recovery marker in this in vivo study (Islam and Sakaguchi, 
2006). 
Unlike most polyols, glucose is rapidly and completely absorbed in the small intestine. Several in 
vivo studies have reported the different absorption pattern of glucose in the small intestine. 
Bogner et al., (1963), reported that glucose absorption was highest in the mid-intestine of female 
chicks, when Lavin(1976) suggested the ileum as a highest glucose absorbing section in the 
small intestine of chicks. On the other hand Riesenfeld et al., (1980) reported a reduction in 
glucose absorption capacity with increasing distance from the pylorous, and later explained that 
the difference in glucose absorption capacity in the different segments of the small intestine may 
be due to variation of concentrations. However, results of our present study did not show much 
difference in glucose absorption index (GAI) between the different segments of the small 
intestine, which corresponds with findings reported by Fearson and Bird(1968). However, the 
significantly reduced GAI in the xylitol fed groups (NXYL and DXYL) compared to their 
corresponding controls (NC and DBC) across the small intestinal segments (more pronounced in 
the 1st and 2nd quarters)correspond with the results of ourin vitroglucose absorption studies, and 
supports the inhibitory potentials of xylitol on intestinal glucose absorption. This may be partly 
involved in the mechanism behind the hypoglycemic as well as anti-diabetic effects of xylitol in 
normal or diabetic conditions. 
Furthermore, in a recent study, Hassan et al., (2010) reported that 3.0 mM acarbose caused 
significant decrease in glucose intestinal absorption in vitro. However in our present study, 
acarbose did not significantly affect intestinal glucose absorption bothin vitro and in vivo 
environment, which could be due to its mode of action. Acarbose is a known alpha amylase and 
alpha glucosidase inhibitor that inhibits the breakdown of glucose-building carbohydrates like 
starch and maltose, hence delaying the release of glucose from carbohydrate (Bischoff, 1994; 
Patel et al., 2012). However, in our study, glucose was used either as a substrate or administered 
orally; hence acarbose did not exert any significant effect on intestinal glucose absorption. 
The rate of nutrient gastric emptying and digesta transit are important factors in gastro intestinal 
nutrient digestion and absorption (Islam and Indarjit, 2012). It has also been reported that faster 
intestinal transit and delayed gastric emptying might be the cause of slow intestinal nutrient 
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absorption and reduced food intake (Salminen et al., 1984; Shafer et al., 1987). In our present 
study, although not significantly, induction of diabetes appreciably increased the rate of nutrient 
gastric emptying, which correspond with the lower phenol distribution in DBC group compared 
to the NC group (Figure 4.4 and 4.5).Although negative energy balance resulting from constant 
hyperglycemiais known as a major reason for the frequent hunger (polyphagia) and increased 
food intake often observed as a classical symptom of diabetes, faster gastric emptying may also 
contribute to this effect. Previous studies have demonstrated a correlation between gastric 
emptying rate and eating rate or satiety (Bergmann et al., 1992; Zhu et al., 2013). However, the 
oral administration of a single bolus dose of xylitol delayed gastric emptying after 1 hour in both 
normal and diabetic rats, which correlates with the higher phenol red distribution in the stomach 
of the xylitol fed rats (Figure 4.4 and 4.5). This trend corresponds to studies previously reported 
by Shafer et al., (1987), and may also be the cause of the reduced food intake in diabetic rats fed 
with xylitol as reported in a very recent study(Islam and Indarjit, 2012). 
Furthermore, despite the delayed gastric emptying caused by a single dose of xylitol 
administration, it also caused a faster digesta transit from the small intestine towards the cecum. 
This, coupled with a concomitant delay of gastric emptying by xylitol, corresponds to data 
published by Salminen et al., (1989) in normal human subjects, and may also contribute to the 
reduced GAI observed in the small intestine of the xylitol treated groups in this study. The 
relatively smaller amount of ingested nutrient or glucose reaching the small intestine from the 
stomach in the xylitol fed groups, as indicated by the slower gastric emptying, and a concomitant 
faster transit of small intestinal nutrient can cause reduced glucose absorption, which may partly 
contribute to the mechanism behind the anti-diabetic as well as hypoglycemic effect of xylitol.  
Also, the volume and transit of intestinal fluid are factors that can play an important role in 
determining the extent of small intestinal nutrient digestion and absorption (Islam and 
Sakaguchi, 2006). A correlation graph of GAI (%) versus fluid volume (mL) showed an inverse, 
but insignificant correlation(p< 0.05) between both parameters (figure 4.8a). In other words, 
where there was lower glucose absorption in the intestine, there was a corresponding higher fluid 
volume in that particular segment of the small intestine. Although, from the correlation plot, not 
all groups satisfied this relationship between absorption and fluid volume (figure 8.4b and c), the 
graph on figure 4.7a and b suggests higher glucose absorption when there was a lower fluid 
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volume in the different segments of the intestine for most groups. Furthermore,Islam and 
Sakaguchi (2006) reported that high intestinal nutrient transit coupled with excessively high 
intestinal fluid volume have the possibility of reducing degradation and absorption by causing 
lesser amounts of intestinal content to come into contact with the intestinal mucosal surface. In 
our present study, the higher intestinal fluid volume and faster nutrient transit in the small 
intestine of the xylitol fed groups may have also contributed to the concomitantly lower glucose 
absorption in the small intestine of these groups. 
 
5.2 Conclusion 
The results from this study suggest that xylitol has inhibitory effects on the activities of 
carbohydrate hydrolyzing enzymes; alpha amylase and alpha glucosidase in vitro, and delay 
effects onsmall intestinal glucose absorption, especially in the duodenal and jejunal segments in 
vitro and in vivo. The results also suggest that xylitol can prolong gastric emptying and increase 
the rate of intestinal nutrient transit in vivo in both normal and diabetic conditions, which may 
partly contribute to its inhibitory potential on intestinal glucose absorption. Furthermore, results 
of this study also suggest that xylitol may also promote the uptake of circulating glucose by 
muscle tissue, which has been proven by our in vitro muscle glucose uptake study. 
The above mentioned hypoglycemic potentials of xylitol, especially in the in vitro study, were 
dose dependent. These effects were shown to be most significant at 30% and 40% concentrations 
of xylitol, which are below the threshold range that can elicit gastrointestinal discomfort in adults 
and children (Bond and Dunning, 2006; Makinen, 1976;Wang and van Eys, 1981). Moreover, it 
has been reported that regular ingestion of xylitol increases tolerance against gastrointestinal 
discomfort caused by xylitol (Wang and van Eys, 1981), and it is also a safer sugar alcohol 
compared to many other available in the market (Islam, 2011). 
In conclusion, the anti-diabetic effects of xylitol may not only be due to inhibition of 
carbohydrate digestion and glucose absorption from the small intestinal mucosa; but may also be 
due to improving insulin action or exhibiting an insulin-like effect on skeletal muscle, thus 
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